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ABSTRACT 
 
 
Peptidomimetics are synthetic oligomers that resemble the activities of peptides. Their 
advantages over peptides include high stability towards proteolysis and enormous chemical 
diversity. Over the past two decades, there have been extensive efforts to develop peptide 
mimics, such as beta-peptides, peptoids, D-peptides, etc. The research on peptidomimetics have 
led to many important applications in both medicinal and material science. In order to explore 
new functions, the discovery of peptidomimetics with novel frameworks is essential. We 
reported the synthesis and evaluation of a new class of peptidomimetics, termed as γ-
AApeptides. Previous studies of γ-AApeptides have revealed that γ-AApeptides are highly 
resistant to proteolysis, and are highly amendable to chemical diversification. However, new 
biological activities and folding properties of γ-AApeptides still need to be explored. In order to 
expand the potential of γ-AApeptides in chemical biology and medicinal chemistry, I have been 
focusing on the development of new methods to synthesize linear and cyclic γ-AApeptides, 
development of one-bead-one-compound (OBOC) γ-AApeptide libraries for the discovery of 
inhibitors against beta-amyloid aggregation, exploring new helical foldamers for the rational 
design of protein-protein interaction (PPI) inhibitors, and studying cyclic γ-AApeptides for 
antimicrobial development. 
 1 
 
 
 
 
 
 
CHAPTER 1: INTRODUCTION 
 
 
1.1 Peptides and Peptidomimetics 
Peptides are involved in virtually all aspects of biological processes, such as signal 
transduction, molecular recognition, bio-catalysis, etc. Thus, they are ideal source of drug 
candidates. It is indeed true, as 19 therapeutic peptides were approved by FDA between 2001 
and 2012.1,2 Although the drug discovery industry is still dominated by small molecule drugs, 
peptides have been more successful than small molecules as therapeutics, considering much less 
effort has been devoted to develop therapeutic peptides than small molecule based drug 
discovery.3 
Compared to small molecules, peptides cover larger chemical space, thus they are more 
specific and less toxic. In addition, several targets that were considered as “undruggable” with 
small molecule drugs, such as protein-protein interactions (PPIs) and protein-nucleic acid 
interactions, have been tackled by therapeutic peptides.4,5 Despite these exciting advantages, 
there are several obstacles that prevent the development of therapeutic peptides.1 Among them, 
the biggest concern is the oral bioavailability and in vivo stability.6 Due to their peptidic nature, 
peptides are prone to degrade in the presence of proteases. In recent years, considerable research 
effort has been focused on improving oral bioavailability and in vivo stability of peptide drug 
leads. By conjugation to active transport enhancer, such as cell and tissue penetrating peptides7,8 
or the immunoglobulin constant region (Fc),9-11 modified peptides exhibit enhanced 
pharmacological properties, such as extended half-life and improved uptake.12 In addition, 
 2 
 
effective delivery systems can protect peptide cargoes from proteolysis and further enhance the 
pharmacokinetics of therapeutic peptides.13,14 
We and others have been trying to solve this problem in a fundamental way. Hence, 
peptidomimetics, unnatural sequence specific oligomers, were designed to not only mimic the 
functions of peptides, but to possess better properties than their natural analogs.15-18 
Peptidomimetics, which incorporate unnatural building blocks, have much enhanced chemical 
diversity.15,17 In addition, they show high in-vivo stability since their modified structure cannot 
be recognized by proteases easily.19 Thus, they may show improved pharmacological 
properties.20-22 
 
Figure 1.1. Chemical structures of α-peptide, peptoid, β-peptide, and γ-AApeptide. 
From a chemical point of view, unnatural building blocks can be derived from α–amino 
acids through backbone extension,16,17,23,24 N-alkylation,7,15 N-replacement,25 Cα-substitution,26 
Cα-replacement,27 and carbonyl replacement28. Among different classes of peptidomimetics, β-
peptides and peptoids are the most well-known. (Figure 1.1) They have demonstrated excellent 
 3 
 
applications, such as mimicking antimicrobial peptides,29,30 mimicking bioactive peptides,31,32 
protein-binding,33-35, biomaterials36, etc. 
1.2 γ-AApeptides 
In order to further expand the chemical scope of peptidomimetics, a new type of peptide 
mimics has been introduced as “γ-AApeptides”.37 They contain N-acylated N-aminoethyl amino 
acid units derived from γ-chiral peptide nucleic acid (γ-PNA). (Figure 1.1) The synthesis of γ-
AApeptide includes solution phase synthesis of γ-AApeptide monomers and solid phase 
synthesis based on fluorenylmethyloxycarbonyl (Fmoc) chemistry.37,38 Previous studies have 
revealed that they are highly stable under physiological conditions.39 Also, γ-AApeptides showed 
promising biological applications, such as disrupting p53/MDM2 interaction,37 mimicking RNA 
binding,38 antimicrobial,40-43 and transactivator of transcription (TAT) peptides,44 and agent for 
positron emission tomography (PET) imaging39. 
1.3 Outline of the Dissertation 
This dissertation provides insight into the synthetic methodologies and secondary 
structures of γ-AApeptides. The high-throughput screening against Aβ40 peptide and the 
development of cyclic γ-AApeptides as potent antimicrobial agents are also discussed. 
In chapter 2, novel methods to prepare both linear and cyclic γ-AApeptides are discussed. 
In chapter 3, combinatorial γ-AApeptides library in a one-bead-one-compound (OBOC) 
fashion was first designed and prepared with methods discussed in chapter 1. The new library 
was demonstrated through the screening against Aβ40 peptide, which successfully yielded a 
potent inhibitor against the aggregation of Aβ40 peptide. 
 4 
 
Chapter 4 focuses the design, synthesis, and biophysics studies of helical mimetics based 
on sulfono- γ-AApeptides. 
Chapter 5 reports the development of cyclic γ-AApeptides as potent antimicrobial agents 
by mimicking antimicrobial peptides. 
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CHAPTER 2: THE SYNTHESIS OF LINEAR AND CYCLIC γ-AAPEPTIDES 
 
 
Note to Reader 
 Contents in this chapter have been previously published in Organic Letters, 2012, 14, 
3446-3449, European Journal of Organic Chemistry, 2014, 8, 1760-1765, and Organic & 
Biomolecular Chemistry, 2015, 13 (3), 672-676 and have been reproduced with permissions of 
American Chemical Society (ACS), John Wiley and Sons, and the Royal Society of Chemistry 
(RSC). 
2.1 Solid Phase Synthesis of γ-AApeptides Using a Novel Submonomeric Approach 
2.1.1 Background 
Unnatural peptidomimetics have been investigated for more than a decade, and are of 
increasing importance in chemical biology and drug discovery.1 Besides being resistant to 
protease degradation and straightforward derivatization, Many classes of peptidomimetics, such 
as β-peptides,2-4 peptoids,5 α/β-peptides,6,7 oligoureas,8,9 azapeptides,10,11 have shown versatile 
biological applications by mimicking structures and functions of bioactive peptides. One of the 
most important applications is to generate short peptide-like oligomeric ligands that specifically 
target proteins of interest, so as to facilitate the discovery of potential drug candidates12 or 
identification of protein-binding molecules.13,14 Such research efforts, with the development of 
proteomics, lead to an unprecedented need for the rapid generation of a chemically diverse 
combinatorial library.15 A very elegant and successful example is the development of peptoid 
combinatorial libraries by Kodadek’s group to identify short peptoid ligands that binds to a range 
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of proteins with excellent specificity and affinity.13,14,16-20 Nonetheless, there are urgent needs to 
develop novel combinatorial libraries with new scaffolds and functional groups in order to 
discover new classes of ligands with enhanced specificity, affinity, and other biological 
properties.  
 
Figure 2.1.1. Representative structure of a native α-peptide and a γ-AApeptide. 
We have recently developed a new class of peptidomimetics termed “γ-AApeptides”, as 
they comprise of N-acylated-N-aminoethyl amino acid building blocks (Figure 2.1.1), and chiral 
side chains are linked to the γ-carbon in the building blocks.21 The other half of the side chains 
are introduced onto the γ-AApeptide scaffold through acylation of the center N in each building 
block using a wide variety of commercially available carboxylic acids, which endow γ-
AApeptides with limitless potential for the generation of chemically diverse library. In contrast 
to α-peptides, each γ-AApeptide unit is comparable to a dipeptide; and γ-AApeptides and α-
peptides of the same lengths project the same number of side chains. As such, there is a strong 
potential to identify γ-AApeptides that can mimic the structures and functions of α-peptides. 
Indeed, similar to other classes of peptidomimetics, γ-AApeptides have been shown to be 
highly resistant to protease degradation.21 More importantly, they are able to disrupt protein-
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protein interactions,21 and mimic the Tat peptide by binding to HIV-1 RNA22 and facilitating 
membrane translocation23 with comparable affinity and efficiency. More recently, we have also 
demonstrated that γ-AApeptides are potential antibiotic agents to combat drug resistance by 
mimicking the mechanism of action of natural antimicrobial peptides.24-26 Thus, it is envisioned 
that there is great potential to identify γ-AApeptide based ligands from a combinatorial library to 
bind to proteins of interest with high specificity and affinity. 
 
Figure 2.1.2. The previous method for the synthesis of γ-AApeptides. 
However, the previous approach of solid phase synthesis of γ-AApeptides (Figure 
2.1.2)21-26 is not suitable for the development of combinatorial libraries. In this method, a γ-
AApeptide sequence is prepared by assembling γ-AApeptide building blocks on solid phase. 
Each building block requires a 3-step synthesis (reductive amination, acylation, and 
deprotection) starting from the corresponding Fmoc-amino aldehyde. For instance, in order to 
prepare a random library of short γ-AApeptides containing three building blocks (6 side chains, 
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comparable to 6-mer peptides), with the availability of 10 Fmoc-amino aldehydes (Rx = 10) and 
10 carboxylic acids (Ry = 10), 100 different building blocks have to be generated, which is 
almost impossible to achieve. 
In order to rapidly develop γ-AApeptide libraries, so as to maximize their biological 
potential, herein we report the development of a novel submonomeric approach for the solid 
phase synthesis of short γ-AApeptides by utilizing an allyl protection. This method circumvents 
the necessity of γ-AApeptide building block preparation, thereby it is expected to greatly 
facilitate the application of γ-AApeptides in biomedical sciences in the future. 
2.1.2 Results and discussion 
The new route for the solid phase synthesis of γ-AApeptides using the submonomeric 
approach is shown in Figure 2.1.3. The first two steps have been used in the microwave-assisted 
preparation of peptoids15 and have proven to be highly efficient. In brief, 2-1-1 is obtained 
through the microwave-assisted coupling of bromoacetic acid with the amino group on the Rink 
amide resin using DIC as the activation agent.15 With the assistance of a 1000W commercial 
microwave, the reaction was accomplished in 4 min (8 × 30 s). Then excess allyl amine is added 
as the nucleophilic agent to form a secondary amine on the solid phase to give 2-1-2, which 
again was assisted by microwave and finished in 4 min (8 × 30 s). We reason the introduction of 
the allyl protecting group is critical since it completely avoids the constant over-alkylation 
occurring in the reductive amination of Fmoc-amino aldehyde with the primary amino group on 
the solid phase.27,28 Although over alkylation can be potentially alleviated by draining out excess 
aldehyde remaining in the solution during the imine formation step, it does not solve the 
problem;27 on the contrary, incomplete imine formation is seen when the draining method is 
used, since the formation of the imine is not efficient.27 As such, successful preparation of 
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sequences employing repetitive reductive amination reactions on the solid phase is rare due to 
such complexity of over-alkylation and incomplete reaction. 
 
Figure 2.1.3. The new route for the synthesis of γ-AApeptides by submonomeric approach. DIC 
= Diisopropylcarbodiimide, PMHS = polymethylhydrosiloxane, DhBtOH = 3-Hydroxy-4-oxo-
3,4-dihydro-1,2,3-benzotriazine. 
With the protection of allyl group, 2-1-3 can be obtained free of side reactions, as the 
reductive amination step can be repeated in order to achieve quantitative conversion. The allyl 
protecting group is selectively removed by using PMHS-ZnCl2/Pd(PPh3)4 in THF for 4 h (twice) 
to provide 2-1-4. Although this method has only been used to convert allyl protected secondary 
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amines to primary amines,29 we found the deprotection of tertiary amines 2-1-3 under same 
condition is also extremely efficient. Followed by double coupling of carboxylic acids and 
deprotection of Fmoc, the first building block 2-1-5 is accomplished, which ends the first 
synthetic cycle on the solid phase. The desired γ-AApeptides therefore can be generated by 
repeating the synthetic cycles. 
To demonstrate the efficiency of this approach, Fmoc-Phe-CHO was first used for the 
reductive amination of 2-1-2a, and CH3COOH was used to acylate 2-1-4a. Both 2-1-4a and 2-1-
5a were cleaved by 95% TFA/H2O, and analyzed by HPLC. As shown in Figure 2.1.4, every 
step in the synthetic cycle, including reductive amination, allyl deprotection, and acylation, is 
highly efficient, as crude 2-1-4a and 2-1-5a shown more than 95% purity. 
 
Figure 2.1.4. HPLC traces of crude 2-1-4a and 2-1-5a that were monitored at 215 nm. 
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Figure 2.1.5. a, random γ-AApeptide sequences 2-1-6a, 2-1-6b, and 2-1-6c. b, Fmoc-amino 
aldehydes and carboxylic acids used to prepare 2-1-6a, 2-1-6b, and 2-1-6c. 
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To further prove the practical application of this approach in the future development of a 
γ-AApeptide combinatorial library, three random γ-AApeptide sequences 2-1-6a, 2-1-6b, and 2-
1-6c (Figure 2.1.5a) were synthesized from a pool of Fmoc-amino aldehydes21-26,30 and 
carboxylic acids (Figure 2.1.5b) that contain a variety of charged and hydrophobic groups. As 
shown in Figure 2.1.5a, 2-1-6a, and 2-1-6b are γ-AApeptides containing three building blocks, 
which are comparable to 6-mer peptides in length; whereas 2-1-6c is a γ-AApeptide having 5 
building blocks, and thereby a 10-mer peptide mimic. We believe these γ-AApeptide sequences 
are sufficiently long enough to compose combinatorial libraries in the future for the 
identification of potential drug candidates or protein binding ligands. If the satisfactory yield of 
these γ-AApeptides can be achieved, this submonomeric approach will definitely be able to be 
used to generate γ-AApeptide libraries much more rapidly than the current building block 
strategy. 
Table 2.1.1 Product characteristics based on the monomeric approach. 
γ-AApeptide 2-1-6a 2-1-6b 2-1-6c 
Purity 68% 62% 59% 
Yield 31% 27% 22% 
 
Surprisingly, the submonomeric method led to the production of these three γ-AApeptide 
sequences with excellent yield and purity (Table 2.1.1, Figure 2.1.6, and Figure 2.1.7). Although 
there are some impurities seen in crude HPLC traces, which may come from the long-time 
exposure of resin to air and to water moisture in the solvents during solid phase synthesis, the 
quality of these crude γ-AApeptides are consistent and considerably high. They can be easily 
purified (Figure 2.1.6) and provided with the excellent overall yields. However, as seen in Figure 
2.1.8, in order to prepare same three γ-AApeptide sequence 2-1-6a, 2-1-6b, and 2-1-6c,6 building 
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blocks would have to be prepared using the previous building block strategy, which is much 
more tedious and time-consuming. Thus, this new submonomeric approach is a real 
breakthrough. 
 
Figure 2.1.6. HPLC profiles of γ-AApeptide 2-1-6a and 2-1-6c. Figure 2.1.6a, top, HPLC trace 
of crude 2-1-6a; bottom, HPLC trace of purified 2-1-6a. Figure 2.1.6b, top, HPLC trace of crude 
2-1-6c; bottom, HPLC trace of purified 2-1-6c. 
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Figure 2.1.7. The HPLC trace of crude γ-AApeptide 2-1-6b. 
 
Figure 2.1.8. The building blocks that are needed to prepare γ-AApeptides 2-1-6a, 2-1-6b, and 
2-1-6c using previous building block strategy. 
2.1.3 Conclusions 
 In summary, we have reported a novel submonomeric method to prepare short γ-
AApeptides. This strategy circumvents the needs to prepare γ-AApeptide building blocks and 
therefore greatly facilitates the rapid preparation of chemically diverse γ-AApeptide libraries. 
The application of this approach will unprecedentedly enhance the biological potential of γ-
AApeptides. The preparation of the γ-AApeptide combinatorial library for specific protein 
targeting is currently under investigation. 
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2.1.4 Experimental section 
General information. α-amino acids and Rink amide resin (0.7 mmol/g, 200-400 mesh) were 
provided by Chem-Impex International, Inc. All other reagents and solvents were purchased 
from either Sigma-Aldrich or Fisher Scientific and used without further purification. The Fmoc-
amino aldehydes were synthesized following previously reported procedure.21-26,30 γ-AApeptide 
sequences were prepared on the Rink amide resin in peptide synthesis vessels on a Burrell Wrist-
Action shaker. The steps used in the microwave were carried out in a 1000W Emerson 
microwave oven (model MW8119SB). The γ-AApeptides were analyzed and purified on an 
analytical and a preparative Waters HPLC system, respectively, and then dried on a Labcono 
lyophilizer. Molecular weights of the compounds and γ-AApeptides prepared on the solid phase 
were identified on an Agilent LC-MS or a Bruker AutoFlex MALDI-TOF mass spectrometer. 
Solid phase synthesis, purification and characterization of γ-AApeptides using the 
submonomeric approach. γ-AApeptides were prepared on a Rink amide resin in peptide 
synthesis vessels on a Burrell Wrist-Action shaker following standard Fmoc chemistry protocol 
of solid phase peptide synthesis. 100 mg of Fmoc-Rink amide resin was shaken in 3 ml of 20% 
piperidine/DMF for 20 min, and the solution was drained. This Fmoc deprotection procedure 
was repeated one more time and then the resin was washed with DMF (4 × 3 mL), and CH2Cl2 (4 
× 3 mL), respectively. 2 M Bromoacetic acid and 2 M DIC in DMF (3 ml) were shaken for 1 min 
and added to the beads. The vessel was placed in the microwave oven for 30 seconds and the 
power was set at 10%. The vessel was then taken out and gently shaken by hands and put back to 
oven. This step was repeated for 8 times, and the beads were washed with DMF (4 × 3 mL), and 
CH2Cl2 (4 × 3 mL), respectively. A solution of allyl amine in DMF was added and the vessel 
was placed into microwave oven with the power set at 10% for 30 seconds. The procedure was 
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repeated for 8 times again, and washed with solutions used above. An Fmoc-amino aldehyde (3 
equiv) in 50% MeOH/ CH2Cl2 was added, followed by the addition of 3 equiv of NaCNBH3, and 
100 µL of CH3COOH in CH2Cl2. The reaction was shaken for 1 h and the solution was drained. 
This reductive amination step was repeated one more time and washed with solutions used 
above. To the beads in 3 mL THF were added polymethylhydrosiloxane (150 µL), Pd(PPh3)4 (20 
mg) and ZnCl2 (30 mg), and the reaction mixture was shaken for 4 h. The solution was drained 
and the deprotection procedure was repeated for one more time. The resin was washed with 
DMF and CH2Cl2 as shown above. A carboxylic acid (5 eqiv.), DIC (5 eqiv.), and DhbtOH (3-4-
Dihydro-3-hydroxy-4-oxo-1-2-3-benzotriazine, 5 eqiv.) in DMF were mixed and added to the 
beads, and shaken for 3 h. The coupling reaction was repeated one more time, and the beads 
were washed with DMF and CH2Cl2 as shown above. 
After the desired sequences were assembled, the resin was transferred into 4 ml vials and 
γ-AApeptides were cleaved from solid support in 95% TFA/H2O for 1h. Then solvent was 
evaporated and the residues were analyzed and purified on an analytical (1 ml/min) and a 
preparative Waters (20 ml/min) HPLC systems, respectively, using 5% to 100% linear gradient 
of solvent B (0.1% TFA in acetonitrile) in A (0.1% TFA in water) over 40 min, followed by 
100% solvent B over 10 min. The HPLC traces were detected at 215 nm. The desired fraction 
were collected and lyophilized. The molecular weights of γ-AApeptides were obtained on Bruker 
AutoFlex MALDI-TOF mass spectrometer using α–cyano-4-hydroxy-cinnamic acid. 
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Table 2.1.2 MS analysis of molecules or γ-AApeptides identified in the text. 
γ-AApeptides molecular weight (Actual) molecular weight (found) 
2-1-4a 429.2 430.2 (M+H+) (LC-MS) 
2-1-5a 471.2 472.2 (M+H+) (LC-MS) 
2-1-6a 862.5 863.4 (M+H+) (LC-MS) 
2-1-6b 804.5 805.5 (M+H+) (LC-MS) 
2-1-6c 1349.8 1351.2 (M+H+) (MALDI) 
 
2.2 Quick Access to Multiple Classes of Peptidomimetics from Common γ-AApeptide 
Building Blocks 
2.2.1 Background 
Peptides are involved in virtually all aspects of life processes, and display remarkable 
biological activities.31 However, they also have a few intrinsic drawbacks for biological 
applications, including the susceptibility to proteolytic degradation. As an alternative approach, 
peptidomimetics have been a vibrant research area in the past two decades, as they are designed 
to capture the structures and functions of peptides, while possessing enhanced stability and 
chemical diversity.32 They have been used for protein surface recognition, disruption of protein-
protein interactions and other important biological functions.12,33-41 However, as peptides and 
proteins display an endless diversity of structures and functions,32 development of new classes of 
peptidomimetics with novel backbones remains to be of considerable significance.42 
 
Figure 2.2.1. The general structure of -peptide and -AApeptide. 
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To this endeavor, We have recently designed a new class of peptide mimics termed “γ-
AApeptides” (Figure 2.2.1),21 as they contain N-acylated-N-aminoethyl amino acid units (Figure 
2.2.1) derived from γ-PNAs.43 In each unit (building block), the chiral side chain is derived from 
an α-amino acid, while the other side chain is introduced through acylation of the nitrogen on the 
backbone by any carboxylic acids or acyl chlorides. As such, each unit of γ-AApeptides is 
comparable to two residues in α-peptides, and γ-AApeptides essentially project an identical 
number of functional groups as α-peptides of the same length. Additionally, the potential of 
generating γ-AApeptides with chemically diverse functional groups is limitless. Furthermore, half 
of the side chains of γ-AApeptides remain chiral, which may impose conformational bias to 
promote the formation of secondary folding structures. Similar to other classes of known 
peptidomimetics, γ-AApeptides are highly resistant to proteolytic degradation,21,44 making them 
promising candidates for modulation and perturbation of biological processes. For instance, some 
γ-AApeptides can permeate mammalian cell membranes,23 bind to HIV-1 RNA with affinity and 
specificity akin to Tat peptide,22 modulate p53/MDM2 protein-protein interactions,21 and 
selectively disrupt bacterial membranes by mimicking the mechanism of natural host-defense 
peptides.24,25,45 Furthermore, γ-AApeptides can even form novel nanostructures,46 suggesting their 
potential application in biomaterial science. To further expand the versatility of γ-AApeptides in 
biomedical and material sciences, herein we report a method to prepare theoretically any γ-
AApeptides with high efficiency. More importantly, using the same synthetic approach, a few new 
classes of peptidomimetics with novel backbones, including oligocarbamates, oligosulfonamides, 
and oligoureas, can be conveniently generated. These peptidomimetics are different from classic 
oligo -carbamates, -sulfonamides and -ureas,47-51 and thus they may lead to novel functions and 
applications in biomedical and material sciences in the future. 
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2.2.2 Results and discussion 
The synthesis of γ-AApeptides was originally carried out on the solid phase using the 
building-block approach.45 Although the synthesis is well established and provides products 
constantly with good yields, the approach is not ideal in quickly generating derivatives with 
diverse groups, because each building block has to be prepared separately before the solid phase 
synthesis is carried out. We recently developed a submonomeric approach for the synthesis of γ-
AApeptides that circumvents the necessity of preparing γ-AApeptide building blocks.52 
However, the basic units Fmoc-amino aldehydes are not stable at room temperature, and as the 
result they have to be used immediately after being prepared. Moreover, the synthetic procedure 
is still tedious and takes a few steps to finish one synthetic cycle, which can significantly affect 
the overall yield if longer sequences are prepared. As such, it is impractical to synthesize γ-
AApeptide libraries with large diversity.  
To overcome the obstacle, herein we report a new method that combines both building-
block and submonomeric approaches. In this approach, only a few N-alloc γ-AApeptide building 
blocks need to be synthesized (Figure 2.2.2) via the route 1 or the route 2,21,25,45 in order to 
prepare γ-AApeptides containing virtually limitless functional diversity. When R contains acid-
labile protecting groups such as Boc, route 2 has to be adopted to remove the benzyl group 
before alloc-Cl is added. It is noted that 1% AcOH is critical in this hydrogenation step to 
protonate the secondary amine, which otherwise always leads to the product with the Fmoc 
group being removed. 
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Figure 2.2.2. Synthesis of γ-AApeptides by a combined building-block and monomeric 
approach. a, synthesis of N-alloc γ-AApeptide building blocks. b, synthesis of γ-AApeptide 
sequences. Alloc = allyloxycarbonyl. 
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Figure 2.2.3. a. N-Alloc γ-AApeptide building blocks 1-5 and acylating agents used for the 
synthesis of the sequences. b. The structure of 2-2-1, and its crude and purified analytical HPLC 
traces. c. The structure of 2-2-2, and its crude and purified analytical HPLC traces. 
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The key step of the solid phase synthesis is the removal of the alloc protecting group. 
Briefly, on the solid phase, the alloc protecting group is removed by 10 mol % equiv. Pd(PPh3)4 
and 6 equiv. Me2NH·BH3 in DCM.53 This reaction is found to be extremely efficient and only 
takes 10 min to give the desired product with the quantitative conversion. After the removal of 
the alloc group, a variety of carboxylic acids or acyl chlorides can then be used to acylate the N 
on the γ-AApeptide backbone. To test the efficiency of this methodology, we synthesized a tetra-
block sequence 2-2-1 and a penta-block sequence 2-2-2 (Figure 2.2.3). As shown in Figure 
2.2.3c, with just one N-alloc γ-AApeptide building block, 2-2-2 was synthesized to bear diverse 
side chains when different acylating agents were used. With the use of multiple N-alloc γ-
AApeptide building blocks and different acylating agents, the sequence 2-2-1 containing a wide 
variety of random side chains was prepared (Figure 2.2.3b). The purity of these two crude 
sequences is more than 80% (Figure 2.2.3b and 2.2.3c), which demonstrates the feasibility of this 
approach for the efficient preparation of γ-AApeptides with diverse functional side chains. 
Compared to previous approaches, this new approach significantly reduces the steps and shortens 
the time of synthesis, and greatly improves the yield and purity of γ-AApeptides. Furthermore, 
N-alloc building blocks are much more stable than Fmoc-amino aldehydes, the basic units used 
in the synthesis of γ-AApeptides52 by submonomeric approach, and therefore they can be 
prepared in large batches and used for a long period of time. This is another versatility of this 
new synthetic method. 
It is known that peptidomimetics such as oligocarbamates, oligosulfonamides, and 
oligoureas also have important biological applications,47-51 implying the promising potential of 
new peptidomimetics with novel functional backbones. However, the synthesis of these classes 
of peptidomimetics is not trivial, which might be the reason why the reports of their biological 
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applications are much less than those based on β-peptides and peptoids. We realized that with 
these same N-alloc γ-AApeptide building blocks, new backbone function entities can be 
introduced to prepare new classes of peptidomimetics. 
 
Figure 2.2.4. a. The N-alloc γ-AApeptide building block, sulfonyl chlorides, chloroformates, 
and isocyanates that were used to prepare new classes of peptidomimetics. b. Solid phase 
synthesis of peptidomimetic sequence with different backbone functionalities. 
To test our hypothesis, we synthesized the oligosulfonamide (2-2-3), oligocarbamate (2-
2-4), oligourea (2-2-5) and the sequence 2-2-6 containing all kinds of backbone functionalities 
using one N-alloc γ-AApeptide building block on the solid phase (Figure 2.2.4 and 2.2.5). The 
synthesis was achieved by acylating the N on the backbone with a variety of commercially 
available sulfonyl chlorides, chloroformates, and isocyanates (Figure 2.2.4a). Both crude and 
purified HPLC spectra demonstrate the efficiency of the synthesis (Figure 2.2.6). It should be 
noted that these new peptidomimetics are different from classic oligo -carbamates, -
sulfonamides, and -ureas47-51 as they are based on γ-AApeptide backbone, and therefore they 
may have discrete structures and functions. Our results demonstrated that with common γ-
AApeptide building blocks, different classes of peptidomimetics can be simultaneously obtained. 
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Figure 2.2.5. The sequences of oligosulfonamide (2-2-3), oligourea (2-2-4), oligocarbamates (2-
2-5), and the sequence containing all backbone functionalities (2-2-6). 
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Figure 2.2.6. Analytical HPLC traces for crude and purified sequences 2-2-3 to 2-2-6. 
2.2.3 Conclusions 
In summary, we have reported a modified method for the efficient preparation of γ-
AApeptides and a few new classes of peptidomimetics such as oligosulfonamides, oligoureas 
and oligocarbamates, using common N-alloc γ-AApeptide building blocks. Now generation of 
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chemically diverse libraries of γ-AApeptides with virtually limitless potential is feasible. In 
addition, our effort not only demonstrates the versatility of this new synthetic approach, 
moreover, it leads to the creation of new families of unprecedented peptidomimetics bearing 
diverse functional backbones and side chains. The further development of these novel 
peptidomimetics may find important biological applications in the future. As such, the potential 
scope of research on γ-AApeptides will be significantly expanded. 
2.2.4 Experimental section 
General information. All Fmoc protected α-amino acids and Rink amide resin (0.7 mmol/g, 
200-400 mesh, 1% DVB) were purchased Chemimpex. All the other solvents and reagents were 
purchased from vendors and used without further purification. NMR data for building blocks was 
obtained on a 400 MHz NMR spectrometer. High resolution masses of building blocks were 
determined on a Liquid Chromatography/Quadrupole Time-of Flight mass spectrometer. Masses 
of peptidomimetics were obtained on a Proteomics Analyzer. Solid phase synthesis was 
conducted in peptide synthesis vessels on a shaker. Oligomers were analyzed and purified on a 
HPLC system, and then lyophilized on a lyophilizer.  
Preparation of γ-AApeptide building blocks. N-alloc γ-AApeptide building blocks 1, 2, 5 were 
synthesized via route 1 in Figure 2.2.2 by following previously reported methods.21,54,55  Building 
blocks 3 and 4 were synthesized via route 2 in Figure 2.2.2 and the procedure for the preparation 
of 3 is briefly shown as follows. The benzyl ester21,54,55 (2 g, 1.66 mmol) in 50 mL methanol 
containing 1% acetic acid, Pd/C (0.2 g, 10% wt) was added. Hydrogenation was conducted at 
atmospheric pressure and room temperature for 2 h. After filtration and evaporation, the 
remaining solid was suspended in 50 mL CH2Cl2 and N, N-diisopropylethylamine (434 µL, 2.49 
mmol, 1.5 eqiv.) was added. The reaction mixture was cooled to 0 oC, then a solution of allyl 
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chloroformate (176 µL, 1.66 mmol, 1 eqiv.) in CH2Cl2 was slowly added over 1h. The mixture 
was allowed to stir at room temperature for two more hours, and then washed with saturated 
citric acid (30 mL x 3) and brine solution, dried over Na2SO4, and concentrated under vacuum. 
The pure building block 3 was obtained as a white foam solid after flash chromatography with 
10% MeOH/CH2Cl2 (1.68 g, 85% yield). 
 
Figure 2.2.7. Building blocks used for synthesizing different classes of oligomers. 
Compound 1. Yield 65%. 1H NMR (CDCl3, 400 MHz) δ (two rotamers) 7.74 (d, J = 8 
Hz, 2H), 7.56 (t, J = 8 Hz, 2H), 7.38 (t, J = 8 Hz, 2H), 7.29 (t, J = 8 Hz, 2H), 5.92-5.73 (m, 1H), 
5.29-5.06 (m, 2H), 4.57-4.28 (m, 5H), 4.17-3.83 (m, 3H), 3.60-3.15 (m, 2H), 1.69-1.23 (m, 3H), 
0.93-0.87 (m, 6H) ppm. 13C NMR (CDCl3, 100 MHz) δ (two rotamers) 173.6, 173.2, 157.8, 
156.8, 156.7, 156.6, 156.2, 143.8, 141.3, 132.3, 124.5, 119.9, 118.2, 117.4, 66.8, 66.6, 52.3, 49.8, 
48.7, 47.2, 41.7, 24.8, 23.2, 22.0, 21.8, 21.7, 14.2 ppm. HR-ESI: [M+H]+ calc: 481.2333, found: 
481.2352. 
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Compound 2. Yield 61%. 1H NMR (CDCl3, 400 MHz) δ (two rotamers) 8.74 (s, 1H), 
7.73 (d, J = 8 Hz, 2H), 7.50-7.47 (m, 2H), 7.36 (t, J = 8 Hz, 2H), 7.28-7.18 (m, 7H), 5.82-5.74 
(m, 1H), 5.21-5.07 (m, 2H), 4.53-4.43 (m, 2H), 4.34-4.25 (m, 2H), 4.11-3.21 (m, 6H), 2.82 (s, 
2H) ppm. 13C NMR (CDCl3, 100 MHz) δ (two rotamers) 173.5, 157.5, 156.9, 156.5, 156.1, 
143.8, 143.7, 141.3, 137.2, 132.2, 129.2, 129.1, 128.6, 127.7, 127.0, 126.7, 125.2, 119.9, 117.6, 
66.9, 60.5, 51.7, 49.8, 49.0, 47.1, 38.8, 21.0, 14.2 ppm. HR-ESI: [M+H]+ calc: 515.2177, found: 
515.2196. 
Compound 3. Yield 85% (from intermediate 6a). 1H NMR (CDCl3, 400 MHz) δ (two 
rotamers) 8.74 (s, 1H), 7.73 (d, J = 8 Hz, 2H), 7.57 (d, J = 8 Hz, 2H), 7.37 (t, J = 8 Hz, 2H), 7.28 
(t, J = 8 Hz, 2H), 5.91-5.79 (m, 1H), 5.28-5.07 (m, 2H), 4.55-4.52 (m, 2H), 4.37-3.92 (m, 5H), 
3.92-3.21 (m, 3H), 3.06-3.02 (m, 2H), 1.42-1.26 (m, 15H) ppm. 13C NMR (CDCl3, 100 MHz) δ 
(two rotamers) 172.8, 156.9, 156.7, 156.4, 156.3, 143.9, 143.8, 141.3, 132.4, 125.0, 119.9, 117.3, 
79.3, 76.8, 66.7, 66.6, 52.1, 50.5, 49.8, 49.1, 47.2, 40.2, 32.1, 29.3, 28.4, 22.8 ppm. HR-ESI: 
[M+Na]+ calc: 618.2786, found: 618.2810. 
Compound 4. Yield 80% (from intermediate 6b). 1H NMR (CDCl3, 400 MHz) δ (two 
rotamers) 9.08 (s, 1H), 8.11 (d, J = 8 Hz, 1H), 7.70 (d, J = 8 Hz, 2H), 7.62-7.21 (m, 10H), 5.84-
5.61 (m, 1H), 5.21-5.07 (m, 2H), 4.55-4.50 (m, 2H), 4.35-4.15 (m, 3H), 4.02-3.71 (m, 3H), 3.48-
2.60 (m, 3H), 1.61 (s, 9H) ppm. 13C NMR (CDCl3, 100 MHz) δ (two rotamers) 173.5, 157.0, 
156.6, 156.4, 156.2, 149.6, 143.8, 141.2, 135.4, 132.2, 132.1, 127.6, 127.0, 125.2, 125.0, 124.5, 
124.0, 123.8, 122.7, 119.9, 118.9, 118.3, 117.6, 116.1, 115.3, 83.7, 83.6, 67.0, 66.8, 51.7, 51.3, 
50.6, 50.5, 49.9, 49.1, 47.1, 28.1 ppm. HR-ESI: [M+H]+ calc: 654.2810, found: 654.2826. 
Compound 5. Yield 75%. 1H NMR (CDCl3, 400 MHz) δ (two rotamers) 7.73 (d, J = 8 
Hz, 2H), 7.55 (t, J = 8 Hz, 2H), 7.37 (t, J = 8 Hz, 2H), 7.29 (t, J = 8 Hz, 2H), 5.85-5.76 (m, 1H), 
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5.29-5.09 (m, 2H), 4.55-4.54 (m, 2H), 4.36-4.15 (m, 3H), 4.04-3.89 (m, 2H), 3.64-3.58 (m, 1H), 
3.43-3.13 (m, 2H), 1.16-0.99 (m, 3H) ppm. 13C NMR (CDCl3, 100 MHz) δ (two rotamers) 173.1, 
157.0, 156.5, 143.8, 141.3, 132.3, 124.9, 119.9, 117.5, 66.9, 66.7, 53.2, 52.9, 49.8, 49.0, 47.2, 
46.4, 18.4 ppm. HR-ESI: [M+H]+ calc: 439.1864, found: 439.1872. 
Compound 6. Yield 80%. 1H NMR (CDCl3, 400 MHz) δ (two rotamers) 9.08 (s, 1H), 
8.11 (d, J = 8 Hz, 1H), 7.70 (d, J = 8 Hz, 2H), 7.62-7.21 (m, 10H), 5.84-5.61 (m, 1H), 5.21-5.07 
(m, 2H), 4.55-4.50 (m, 2H), 4.35-4.15 (m, 3H), 4.02-3.71 (m, 3H), 3.48-2.60 (m, 3H), 1.61 (s, 
9H) ppm. 13C NMR (CDCl3, 100 MHz) δ (two rotamers) 173.5, 157.0, 156.6, 156.4, 156.2, 
149.6, 143.8, 141.2, 135.4, 132.2, 132.1, 127.6, 127.0, 125.2, 125.0, 124.5, 124.0, 123.8, 122.7, 
119.9, 118.9, 118.3, 117.6, 116.1, 115.3, 83.7, 83.6, 67.0, 66.8, 51.7, 51.3, 50.6, 50.5, 49.9, 49.1, 
47.1, 28.1 ppm. HR-ESI: [M+H]+ calc: 654.2810, found: 654.2826. 
Solid phase synthesis and characterization of γ-AApeptides and other classes of 
peptidomimetics. Solid phase synthesis was conducted in peptide synthesis vessels on a Burrell 
Wrist-Action shaker. 100 mg Rink amide resin (0.07 mmol) was treated with 3 mL 20% 
Piperidine/DMF solution for 15 min (× 2) to remove Fmoc protecting group. The solution was 
drained and beads were washed with DCM (3 × 3 mL) and DMF (3 × 3mL). A solution of N-
alloc γ-AApeptide building block (2 eqiv.), HOBt (38 mg, 0.28 mmol), and DIC (44 µL, 0.28 
mmol) in 3 mL DMF was shaken for 5 min, and then added to the resin. The mixture was 
allowed to react at room temperature for 6 h and drained. The beads were washed with DCM (3 
× 3 mL) and DMF (3 × 3 mL), followed by a capping reaction with 500 µL acetic anhydride in 3 
mL Pyridine. After washing with DMF (3 × 3 mL) and DCM (3 × 3 mL), to the beads were 
added Pd(PPh3)4 (8 mg, 0.007 mmol)  and Me2NH·BH3 (25 mg, 0.42 mmol) in 3 mL DCM. 53 
The alloc deprotection reaction was shaken for 10 min and repeated one more time. The beads 
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were washed with DCM and DMF, followed by the reaction with acylating agents (4 eqiv.) and 
DIPEA (6 eqiv.) in 3 mL DCM for 30 min (× 2) or with carboxylic acid (4 equiv.), HOBt (8 
eqiv.), and DIC (8 eqiv.) for 4 h (× 2). The previous steps were repeated until the desired 
sequences were obtained. After that, the resin were washed with DCM and dried in vacuo. 
Peptide cleavage was done in a 4 mL vial by treating resin with TFA/H2O/TIS (95/2.5/2.5) for 2 
h. The solvent was evaporated and the crude was analyzed and purified on an analytical (1 
mL/min) and a preparative (20 mL/min) Waters HPLC systems, respectively. 5% to 100% linear 
gradient of solvent B (0.1% TFA in acetonitrile) in A (0.1% TFA in water) over 40 min was 
used. The HPLC traces were detected at 215 nm. The products were confirmed by MALDI-TOF. 
Table 2.2.1 MALDI analysis of γ-AApeptides. 
γ-AApeptides Purity (Based 
on crude HPLC 
trace) 
Yield (based on 
loading of the 
resin) 
Exact mass 
(Actual) 
Exact mass (found 
by MAIDI-TOF) 
2-2-1 82% 15% 1159.7522 1160.8005 (+ H+) 
2-2-2 86% 18% 1045.6324 1046.5728 (+ H+) 
2-2-3 80% 17% 1129.3735 1130.4100 (+ H+) 
2-2-4 50% 15% 1159.7190 1160.6294 (+ H+) 
2-2-5 55% 12% 1055.5288 1056.5046 (+ H+) 
2-2-6 60% 11% 1144.5045 1145.5491 (+ H+) 
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2.3 The Synthesis of Head-to-tail Cyclic Sulfono-γ-AApeptides 
2.3.1 Background 
Cyclic peptides play an important role in the area of drug discovery.56 The 
conformational rigidity conferred by macrocyclization is often associated with increased 
activities compared with linear peptides, especially in the modulation of protein-protein 
interactions (PPIs).57-60 Over the years, extensive efforts have been focused on the synthesis and 
structural modification of cyclic peptides.61-63 In the meantime, a number of classes of 
peptidomimetics were developed to mimic the structure of peptides.32,64 These compounds were 
shown to display similar, even enhanced functions compared to peptides and possess much better 
stability towards proteolysis.32 Similar to peptides, conformational constraints, such as 
cyclization, have been introduced to peptidomimetics such as peptoids, further enhancing their 
structural rigidity and therefore potential biological activity.65-68 
 
Figure 2.3.1. Structural presentation of a γ-AApeptide as compared with an α-peptide. 
To expand the structural diversity of peptidomimetics, we have recently developed a new 
class of peptidomimetics termed as “γ-AApeptides”.54 γ-AApeptides contain N-acylated N-
aminoethyl amino acid units derived from γ-PNAs (Figure 2.3.1). They can be efficiently 
synthesized by solid phase synthesis methods.54,69,70 Previous studies of γ-AApeptides have 
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revealed that γ-AApeptides are highly resistant to proteolysis and are highly amendable to 
chemical diversification.71 In addition, many γ-AApeptides were reported to bear promising 
biological functions.55,71-78 We thus believe that further development of γ-AApeptides will 
broaden the scope of their applications in the future. 
Inspired by cyclic peptides and cyclic peptidomimetics, we also seek to extend the 
structural and functional diversity of γ-AApeptides by macrocyclization. In an initial study, an 
on-resin head-to-side chain cyclization method was successfully developed75 and resulted in the 
efficient preparation of cyclic γ-AApeptides that exhibited broad-spectrum antimicrobial 
activities superior to those of linear γ-AApeptides.75 However, since the cyclization was on the 
side chains, the resulting cyclic γ-AApeptides exhibited asymmetrical structures, and therefore 
structural studies and rational design of those cyclic sequences are difficult. As such, we have 
directed interest toward the development of the head-to-tail cyclic γ-AApeptides, especially 
cyclic sulfono-γ-AApeptides which may present a more rigid structure by avoiding cis-trans 
isomerization of tertiary amide bonds in a γ-AApeptide. Herein, we report for the first time an 
efficient method for the synthesis of cyclic sulfono-γ-AApeptides in a head-to-tail fashion. In 
order to assess the potential of cyclic sulfono-γ-AApeptides to mimic functions of peptides, 
structural analysis of a three-membered cyclic sulfono-γ-AApeptide 2-3-5 was subsequently 
conducted. 
2.3.2 Results and discussion 
Among successful methods for peptide macrocyclization, in-solution head-to-tail 
cyclization of linear peptide precursors in the presence of powerful coupling reagents has found 
the greatest number of applications. We initially attempted to synthesize linear sulfono-γ-
AApeptide precursors by following the similar method. As such, a regular Fmoc γ-AApeptide 
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building block54 was first attached on the 2-chlorotrityl chloride (CTC) resin (Figure 2.3.2a). The 
Fmoc protecting groups were subsequently removed by 20% piperidine in DMF. However, 
ninhydrin test of the resulting resin showed negative, indicative of the failure of the first attempt. 
The LCMS analysis of Fmoc deprotection elution revealed the ketopiperazine formation during 
the Fmoc-deprotection process (Figure 2.3.2a). This is not surprising, as a similar phenomenon 
was observed on the attempted synthesis of cyclic PNAs.79 Since γ-AApeptides have the same 
backbone as chiral PNA, it is reasonable that synthesis of γ-AApeptides on CTC resin was 
unsuccessful. 
 
Figure 2.3.2. a Ketopiperazine formation, which prevents the sequence elongation. b Aryl 
hydrazine linker and 4-sulfamylbutyryl “safety-catch” linker used to eliminate ketopiperazine 
formation. 
It is known that the formation of ketopiperazines that lead to self-cleavage off the solid 
support is significant under basic condition.79 Thus, we hypothesized that if the reaction is 
carried out under neutral condition, the potential formation of ketopiperazine would be 
minimized. As such, we introduced the Fmoc-N-Alloc γ-AApeptide building block (Figure 
2.3.3A), with the assumption that neutral Alloc deprotection condition could bypass the auto-
cleavage of ketopiperazines.  
 36 
 
 
Figure 2.3.3. (A) Scheme for the preparation of cyclic sulfono-γ-AApeptide 2-3-1. (B) 
Structures of cyclic sulfono-γ-AApeptides in this study. aAcetic acid: trifluoroethanol: 
dichloromethane = 1:1:8 for 2h; boptimized cyclization condition: 0.5 mM linear precursors in 
dichloromethane with O-(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyl-uronium tetrafluoroborate 
(TBTU) (3 equiv.), hydroxybenzotriazole (HOBt) (3 equiv.), and 4-dimethylaminopyridine 
(DMAP) (5 equiv.) at room temperature for 6 h. 
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We then tested the feasibility of this method by synthesizing a four-membered cyclic 
sulfono-γ-AApeptide 2-3-1. (Figure 2.3.3A) In a general method, an Fmoc-N-Alloc γ-AApeptide 
building block (γ-BB-1) was first attached on the CTC resin. Fmoc protecting groups were 
removed by 20% piperidine/DMF solution, followed by the modification of the secondary amine 
by methanesulfonyl chloride. Next, the Alloc protecting groups were removed in the presence of 
Pd(PPh3)4 and Me2NH.BH3 in dichloromethane,53 which indeed significantly prevented 
ketopiperazine formation. The rest of residues in the sequence were assembled with the regular 
γ-AApeptide synthesis method.70 Linear protected sulfono-γ-AApeptides were cleaved from the 
solid support with the regular CTC resin cleavage cocktail (acetic acid: trifluoroethanol: 
dichloromethane = 1:1:8). Finally, seven conditions were investigated for the efficiency of head-
to-tail cyclization in solution (Table 2.3.1). We first employed PyBOP and HBTU (entry 1 and 
2), which are common activating agents for peptide lactamization.86,87 Both of them gave modest 
results with 70% and 55% yields for PyBOP and HBTU, respectively. Surprisingly, an 
alternative method with the use of EDC88 (entry 3 and 4) showed even poorer yield (<5%). The 
most efficient cyclization was performed in dichloromethane with TBTU, HOBt, and DMAP as 
coupling reagents (entry 6).89 Under this condition, the four-membered cyclic sulfono-γ-
AApeptide 2-3-1 was prepared with high yield (>95%) based on the analytical HPLC trace of the 
crude compound (Figure 2.3.4). No oligomerization was detected. 
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Table 2.3.1 Cyclization conditions for 2-3-1. 
entry cyclization conditions a (equiv) solvent yieldb (%) 
1 PyBOP/HOBt/i-Pr2NEt (4, 4, 8) DMF 70 
2 HBTU/HOBt/i-Pr2NEt (4, 4, 8) DMF 55 
3 EDC/HOBt/i-Pr2NEt (4, 4, 8) DMF <5 
4 EDC/HOBt/i-Pr2NEt (4, 4, 8) CH2Cl2 <5 
5 TBTU/HOBt/i-Pr2NEt (3, 3, 5) DMF 50 
6 TBTU/HOBt/DMAP (3, 3, 5) CH2Cl2 95 
7 TBTU/HOBt/DMAP (3, 3, 5) DMF 70 
aThe cyclization reactions were conducted with 0.5 mM linear precursor at room temperature for 
6 h. bYields were determined by analytical HPLC traces. PyBOP: benzotriazol-1-yl-oxytri-
pyrrolidinophosphonium hexafluoro-phosphate; HBTU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophos-phate; EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbo-
diimide. 
 
Figure 2.3.4. HPLC trace of crude cyclic sulfono-γ-AApeptide 2-3-1. 
Thus, the optimized coupling condition was selected to synthesize more cyclic sequences 
so as to demonstrate its generality. It is known that the ring size is another factor that affects the 
efficiency of synthesis. For instance, cyclization of ring sizes less than seven amino acids in 
peptides are sometimes problematic due to the backbone steric strain.90 To test the efficiency of 
cyclization, we investigated the effects of ring size on the cyclization of sulfono-γ-AApeptides 
by the preparation of a two-, a three-, and a five-membered cyclic sulfono-γ-AApeptide, 2-3-2, 
2-3-3, and 2-3-4 respectively. Surprisingly, all of them showed high yields (Table 2.3.1). Even 
the shortest one 2-3-2, which bears same backbone size as a cyclotetrapeptide, displayed 
remarkable high yields. Short cyclic peptides, such as cyclotetrapeptides have attracted a lot of 
attention for their potent biological activities.91 However, the synthesis still remain a challenge.62 
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Providing the highly efficient synthetic method, short cyclic sulfono-γ-AApeptides may serve as 
a novel scaffold to mimic the biological functions of short cyclic peptides. In addition, such 
method can be employed to prepare amphiphilic cyclic sequences (2-3-6 and 2-3-7) with more 
than 50% yield (Table 2.3.1). 
The functions of peptides/peptidomimetics are tightly associated to their structures. 
Therefore, it is very intriguing to probe the structural conformation of head-to-tail cyclic sulfono-
γ-AApeptides, so as to rationally design new molecules with predictable functions. To this end, 
we have successfully obtained a monocrystal of the three-membered cyclic sulfono-γ-AApeptide 
2-3-5 by diffusing pentane vapor into a chloroform solution of 2-3-5. The structure was then 
elucidated by X-ray crystallographic study (Figure 2.3.5).  
 
Figure 2.3.5. (A) Crystal unit cell of cyclic sulfono-γ-AApeptide 2-3-5. (B) Side view of the 
crystal structure showing spatial segregation of side chains. (C) Top view of the backbone with 
subunit 1, 2, and 3. (D) Superimposition of 2-3-5 backbone (red) with a turn region of a type II β 
turn (PDB: 1YCC) (yellow). 
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The crystal unit cell contains two 2-3-5 molecules, with each molecule displays 
segregated side chains on two faces. The top face is comprised of two 4-chlorophenyl sulfonyl 
groups and a methyl group whereas the bottom face contains two methyl groups and a 4-
chlorophenyl sulfonyl group. All three tertiary sulfonamide groups adopt anti conformations. 
The unusual asymmetry of 2-3-5 contradicts what is predicted based on its primary structure as 
well as observed from other macrocycles, such as cyclohexapeptoids.65,88,92 
The backbone of 2-3-5 displays a “twisted” boat-like shape containing three trans amide 
bonds. (Figure 2.3.5B) Two carbonyl groups point outside the ring and one inside the ring. The 
dihedral angles were calculated and presented in Table 2.3.4. Six torsion angles and 
ω are defined to describe backbone dihedral angles of a γ-AApeptide (Table 2.3.4). Noticeable 
variations in dihedral angles  and  of the three subunits present the asymmetry of this 
molecule. Similar to cyclic peptoids,  values show almost planar geometry for all three 
subunits.65 Three trans amide bonds are also revealed by ω values. The mean ω value is 179.2° 
with a standard deviation of 7.5°, which is close to what was reported for cyclic peptides93.  
The backbone also displays a hydrogen bond between C=O (subunit 1) and N-H (subunit 
3), suggesting a turn-like structure. The turn contains same number of atoms as a peptide β-turn 
motif. Two carbon atoms (Cα1 and Cγ3), which mimic two Cα atoms in a peptide β-turn motif, 
show close proximity (6.103 Å). In addition, superimposition of 2-3-5 backbone at the turn 
region of a type II β turn (PDB: 1YCC) reveals high similarity (Figure 2.3.5D). The preference 
of 2-3-5 to resemble type II β turn is shown by comparison with a type I β-turn (Figure 2.3.8). 
The structural conformation of 2-3-5 suggests the potential of cyclic sulfono-γ-AApeptides to 
mimic the protein type II β-turn structure. Such β-turn mimics may find applications in various 
biomedical and material research. 
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2.3.3 Conclusions 
In conclusion, we report an efficient method for the preparation of unprecedented head-
to-tail cyclic sulfono-γ-AApeptides. Keto-piperazine formation was greatly reduced by 
introducing a unique Fmoc-N-Alloc γ-AApeptide building block for the first attachment on the 
CTC resin. Head-to-tail macrocyclization of the linear precursors was achieved with high 
efficiency by using TBTU, HOBt, and DMAP as coupling reagents. Following this method, 
cyclic sulfono-γ-AApeptides varying from two subunits to five subunits were readily synthesized 
with high yields. In order to elucidate its structural properties, we present for the first time the X-
ray crystal structure of a three-membered cyclic sulfono-γ-AApeptide 2-3-5. The crystal 
structure shows a spatial segregation of side chains in an unusual asymmetrical pattern. More 
interestingly, 2-3-5 exhibits a turn-like structure with patterns similar to a peptide type II β-turn 
structure. By demonstrating the robust synthetic method of cyclic sulfono-γ-AApeptides, their 
capability to mimic peptide β-turn structure, and the ability to introduce different side functional 
groups, we believe that such macrocycles will find important applications soon after. 
2.3.4 Experimental section 
General information. All Fmoc protected/unprotected α-amino acids were purchased from 
Chem-Impex International, Inc. 2-Chlorotrityl (CTC) resin (0.98 mmol/g, 200-400 mesh) was 
purchased from AAPPTec LLC. All the other solvents and reagents were purchased from either 
Sigma-Aldrich or Fisher Scientific. NMR data for γ-AApeptide building blocks were analyzed 
on a Varian UnityInova400 spectrometer. Masses of AApeptide building blocks and cyclic 
sulfono-γ-AApeptides were obtained on an Agilent 6540 liquid chromatography/quadru-pole 
time-of-flight mass spectrometer. The X-ray diffraction data for 2-3-5 was collected on a Bruker 
D8 Venture PHOTON 100 CMOS system equipped with a Cu Kα INCOATEC Imus micro-
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focus source (λ = 1.54178 Å). Solid phase synthesis was conducted in peptide synthesis vessels 
on a Burrell Wrist-Action shaker. Cyclic sulfono-γ-AApeptides were analyzed and purified on a 
Waters Breeze 2 HPLC system, and then lyophilized on a Labcono lyophilizer. 
 
Figure 2.3.6. γ-AApeptide building blocks used in the study. 
Figure 2.3.7. Synthetic scheme of Fmoc-N-Alloc γ-AApeptide building block γ-BB-1. 
Synthesis and characterization of γ-AApeptide building blocks. A solution of compound 194 
(4.38 g, 15 mmol) in 100 mL methanol was stirred in an ice bath. A solution of Gly-OtBu.HCl 
(2.52 g, 15 mmol) and triethylamine (2.09 mL, 15mmol) in 20 mL methanol was added to the 
reaction flask. The reaction was allowed to stir at 0 oC for one hour, followed by the addition of 
acetic acid (4 mL, 3% v/v) and sodium cyanoborohydride (1.88 g, 30 mmol). The reaction was 
stirred at 0 oC for two more hours. After completion, methanol was removed by vacuum. The 
resulting slurry was dissolved in saturated sodium bicarbonate solution (150 mL) and 
dichloromethane (150 mL). The mixture was transferred to a separatory funnel. The bottom layer 
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was collected and washed with water (150 mL), then brine solution (150 mL). The organic layer 
was collected, dried over sodium sulfate, and concentrated in vacuo. The pure product 2 was 
obtained as white foam with a yield of 75% after flash column with hexane/ethyl acetate (2:1) as 
eluent. TLC analysis showed an Rf value of 0.1 in 1:1 hexane/ethyl acetate solution. Compound 
2 (70% yield). 1H NMR (CDCl3, 400 MHz) δ 7.26 (t, J = 8 Hz, 2H), 7.22 (d, J = 8 Hz, 1H), 7.16 
(d, J = 8 Hz, 2H), 6.11 (d, J = 8 Hz, 1H), 5.84-5.75 (m, 1H), 5.20 (d, J = 16 Hz, 1H), 5.13 (d, J = 
12 Hz, 1H), 4.50-4.38 (m, 2H), 4.20 (t, J = 8 Hz, 1H), 3.75-3.65 (m, 2H), 3.38-3.08 (m, 2H), 
2.98-2.78 (m, 2H), 1.39 (s, 9H) ppm. 13C NMR (CDCl3, 100 MHz) δ 165.1, 156.6, 136.3, 132.5, 
129.0, 128.7, 127.0, 117.5, 84.5, 65.9, 50.2, 49.7, 47.7, 38.8, 27.8 ppm. HR-ESI: [M+H]+ calc: 
349.2122, found: 349.2120. 
A solution of 2 (3.9 g, 11.2 mmol) and N, N-diisopropylethylamine (2.15 mL, 12.3 mmol) 
in 50 mL dichloromethane was stirred in an ice bath. A solution of Fmoc-OSU (4.15 g, 12.3 mmol) 
in 20 mL dichloromethane was added dropwise. The reaction was allowed to stir at 0 oC for two 
hours. After completion, solvent was removed by vacuum. The slurry was used directly in the next 
reaction. 
The slurry was treated with 20 mL 1:1 dichloromethane/trifluoroacetic acid mixture for 1 
h at room temperature. After completion, solvent was removed by vacuum. Trifluoroacetic acid 
was removed completely by co-evaporation with dichloromethane (20 mL x 5). Pure γ-BB-1 was 
obtained as white solid with a yield of 95% after flash column with hexane/ethyl acetate (1:1) as 
eluent. TLC analysis showed an Rf value of 0.1 in a hexane/ethyl acetate 1:1 solution. γ-BB-1 (65% 
yield, two steps from 2) 1H NMR (CDCl3, 400 MHz) δ (two rotamers) 9.73 (s, 1H), 7.76-7.69 (m, 
2H), 7.55-7.48 (m, 2H), 7.38-7.17 (m, 9H), 5.83-5.69 (m, 1H), 5.25-5.03 (m, 2H), 4.64-4.79 (m, 
4H), 4.22-4.00 (m, 2H), 3.88-3.57 (m, 1H), 3.29-3.81 (m, 2H), 2.79-2.37 (m, 2H) ppm. 13C NMR 
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(CDCl3, 100 MHz) δ (two rotamers) 173.4, 156.9, 156.5, 156.4, 156.0, 143.8, 143.7, 143.6, 141.4, 
141.2, 137.3, 137.1, 132.6, 129.4, 129.2, 129.0, 128.5, 127.7, 127.4, 127.1, 126.6, 124.9, 124.6, 
119.9, 117.6, 117.5, 117.4, 68.2, 67.2, 65.5, 51.6, 51.5, 51.1, 48.9, 47.1, 38.7, 38.5 ppm. HR-ESI: 
[M+H]+ calc: 515.2177, found: 515.2165. 
Figure 2.3.8. Synthetic scheme of N-Alloc γ-AApeptide building block γ-BB-2. 
Compound 4 and γ-BB-2 were prepared from 395 following similar procedure as γ-BB-1.  
Compound 4 (75% yield). H NMR (CDCl3, 400 MHz) δ 6.01 (d, J = 8 Hz, 1H), 5.92-5.82 
(m, 1H), 5.29 (d, J = 16 Hz, 1H), 5.20 (d, J = 12 Hz, 1H), 4.60-4.44 (m, 2H), 4.16-4.11 (m, 1H), 
3.80 (s, 2H), 3.32-3.14 (m, 2H), 1.46 (s, 9H), 1.29 (d, J = 8 Hz, 3H) ppm. 13C NMR (CDCl3, 100 
MHz) δ 165.2, 156.8, 132.5, 117.8, 84.7, 66.1, 52.4, 47.9, 44.4, 27.8, 18.5 ppm. HR-ESI: [M+H]+ 
calc: 273.1809, found: 273.1820. 
γ-BB-2 (70% yield, two steps from 4). 1H NMR (CDCl3, 400 MHz) δ (two rotamers) 9.99 
(s, 1H), 7.76-7.70 (m, 2H), 7.56-7.49 (m, 2H), 7.41-7.24 (m, 4H), 5.88-5.80 (m, 1H), 5.38-5.09 
(m, 2H), 4.66-4.40 (m, 4H), 4.22-4.15 (m, 1H), 4.03-3.89 (m, 2H), 3.56-2.89 (m, 2H), 1.14-0.80 
(m, 3H) ppm. 13C NMR (CDCl3, 100 MHz) δ (two rotamers) 173.7, 156.7, 143.7, 143.5, 141.4, 
141.3, 132.5, 124.6, 120.0, 119.9, 117.7, 68.3, 67.4, 65.8, 53.2, 52.5, 49.1, 48.9, 47.1, 46.3, 45.4, 
18.4, 17.9 ppm. HR-ESI: [M+H]+ calc: 439.1864, found: 439.1867. 
 45 
 
γ-BB-3 was synthesized following previous reported procedure.70 
Synthesis and characterization of cyclic sulfono-γ-AApeptides. 2-3-1: 2-Chlorotrityl chloride 
(CTC) resin (102 mg, 100 μmol) was swelled in 2 mL DCM for 15 min. The first attachment was 
conducted by adding building block γ-BB-1 (77 mg, 150 μmol) and DIPEA (26 μL, 150 μmol) to 
the beads in the reaction vessel, which was allowed to shake at room temperature for two hours. 
After that, the reaction solution was drained, followed by washing with DMF (2 mL x3) and 
DCM (2 mL x3). The unreacted residues were capped with 2 mL methanol for 30 min. Again, 
the beads were washed with DCM (2 mL x3) and DMF (2 mL x3). The Fmoc group was 
removed by treating beads with 20% piperidine/DMF (v/v) solution for 10 min (x2) at room 
temperature. The solution was drained, followed by washing with DMF (2 mL x3) and DCM (2 
mL x3). N-modification was achieved by reacting beads with methanesulfonyl chloride (23 μL, 
300 μmol) and DIPEA (52 μL, 300 μmol) for 30 min (x2) at room temperature. The solution was 
then drained. After washing with DMF (2 mL x3) and DCM (2 mL x3), the beads were treated 
with Pd(PPh3)4 (12 mg, 10 μmol) and Me2NH.BH3 (35 mg, 600 μmol) in 2 mL dichloromethane 
for 10 min (x2) to remove Alloc protecting group.53 After the reaction, the solution was drained. 
The beads were washed with DCM (2 mL x3), 0.2% TFA/DCM (2 mL 60s x3), DCM (2 mL x3), 
5% DIPEA/DCM (2 mL 60s x3), and DCM (2 mL x3).  
For the next coupling reaction, building block γ-BB-3 (88 mg, 200 μmol), DIC (63 μL, 400 
μmol), and HOBt (61 mg, 400 μmol) were pre-mixed in 2 mL DMF for 5 min before getting 
transferred to the reaction vessel. The reaction was shaken at room temperature for 2 hours, and 
the solution was drained. The beads were washed with DMF (2 mL x3) and DCM (2 mL x3) and 
the coupling reaction was repeated. The beads were washed with DMF (2 mL x3) and DCM (2 
mL x3). The N-Alloc was removed following the same conditions discussed above: Pd(PPh3)4 (12 
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mg, 10 μmol) and Me2NH.BH3 (35 mg, 600 μmol) in 2 mL dichloromethane for 10 min (x2). After 
the reaction, the solution was drained. The beads were washed with DCM (2 mL x3), 0.2% 
TFA/DCM (2 mL 60s x3), DCM (2 mL x3), 5% DIPEA/DCM (2 mL 60s x3), and DCM (2 mL 
x3). After that, the beads were treated with phenylmethanesulfonyl chloride (57 mg, 300 μmol) 
and DIPEA (52 μL, 300 μmol) for 30 min (x2) at room temperature for the second Nα-modification. 
After washing with DCM (2 mL x3) and DMF (2 mL x3), N-terminal Fmoc group was removed 
with 20% piperidine/DMF (v/v) solution for 10 min (x2) at room temperature. 
The previous reaction cycle was repeated until the desired sequence was obtained. The 
linear sulfono-γ-AApeptide was cleaved from resin with 4 mL cleavage cocktail (acetic acid : TFE : 
DCM = 1:1:8). After cleavage for 2 h, the solution was collected. The remaining beads were 
washed with 2 mL cleavage cocktail solution for three times. All the solution was combined and 
concentrated by vacuum. Acetic acid was completely removed by co-evaporation with hexane. 
In the cyclization reaction, crude linear sulfono-γ-AApeptide was dissolved in 200 mL 
DCM (~0.5 mM), followed by the addition of coupling reagents: TBTU (96 mg, 300 μmol), HOBt 
(46 mg, 300 μmol), and DMAP (61 mg, 500 μmol). The reaction was allowed to stir at room 
temperature for overnight. After completion of reaction, the solution was washed with 0.1 M HCl 
(100 mL x3), water (100 mL), and brine (100 mL). The DCM layer was collected, dried over 
anhydrous sodium sulfate, and concentrated by vacuum. Crude compound 2-3-1 was dissolved in 
10 mL water/acetonitrile (1:1) solution and filtered through a Whatman filter unit (0.45 μm) before 
HPLC analysis. Pure 2-3-1 was obtained as white powder after preparative HPLC and 
lyophilization. 
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2-3-2 to 2-3-7: Following similar method as 2-3-1, 2-3-2 to 2-3-7 (all white powder) were 
synthesized and characterized by HRMS (Table 2.3.2). 2-3-6 and 2-3-7 were treated with 2 mL 
DCM/TFA (1:1) for 1 h, before HPLC analysis and purification. 
 
2-3-1 1H NMR (DMSO-d6, 400 MHz) δ 8.23 (d, J = 8 Hz, 1H), 8.13-8.07 (m, 2H), 7.38-
7.33 (m, 15H), 7.23-7.17 (m, 5H), 4.54-4.37 (m, 6H), 4.03-3.95 (m, 3H), 3.94-3.75 (m, 8H), 3.20-
2.99 (m, 8H), 2.97 (s, 3H), 1.04 (d, J = 8 Hz, 9H) ppm. 
 
2-3-2 1H NMR (DMSO-d6, 400 MHz) δ 7.60 (d, J = 8 Hz, 1H), 7.43 (d, J = 8 Hz, 1H), 
7.41-7.36 (m, 5H), 7.29-7.22 (m, 5H), 4.64-4.49 (m, 2H), 4.09-3.84 (m, 4H), 3.67-3.51 (m, 3H), 
3.26-3.13 (m, 4H), 3.00 (s, 3H), 1.00 (d, J = 8 Hz, 3H) ppm. 
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2-3-3 1H NMR (DMSO-d6, 400 MHz) δ 8.30 (d, J = 8 Hz, 1H), 8.05 (t, J = 8 Hz, 2H), 7.37 
(s, 10H), 7.26-7.19 (m, 5H), 4.55-4.42 (m, 4H), 3.96-3.89 (m, 3H), 3.86-3.69 (m, 6H), 3.30-3.06 
(m, 6H), 3.02 (s, 3H), 1.05 (t, J = 8 Hz, 6H) ppm. 
 
2-3-4 1H NMR (DMSO-d6, 400 MHz) δ 8.23 (d, J = 8 Hz, 2H), 8.16 (q, J = 8 Hz, 2H), 7.35 
(s, 20H), 7.23-7.12 (m, 5H), 4.52-4.35 (m, 8H), 4.10-4.00 (m, 5H), 3.96-3.80 (m, 10H), 3.25-3.03 
(m, 10H), 2.98 (s, 3H), 1.00 (t, J = 8 Hz, 12H) ppm. 
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2-3-5 1H NMR (DMSO-d6, 400 MHz) δ 7.89 (d, J = 8 Hz, 3H), 7.83-7.79 (m, 6H), 7.67-
7.64 (m, 6H), 3.90 (d, J = 16 Hz, 3H), 3.71-3.61 (m, 9H), 3.23-3.06 (m, 6H), 0.98 (d, J = 8 Hz, 
9H) ppm. 
 
2-3-6 1H NMR (DMSO-d6, 400 MHz) δ 7.68 (s, 6H), 7.56 (s, 2H), 7.41-7.38 (m, 10H), 
4.65 (q, J = 16 Hz, 4H), 3.96 (d, J = 16 Hz, 2H), 3.73-3.68 (m, 4H), 3.18-3.12 (m, 4H), 2.75-2.71 
(m, 4H), 1.51-1.46 (m, 4H), 1.33-1.24 (m, 8H) ppm. 
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2-3-7 1H NMR (DMSO-d6, 400 MHz) δ 8.53-8.07 (m, 3H), 7.68 (s, 9H), 7.38-7.29 (m, 
15H), 4.61-4.41 (m, 4H), 4.20-4.08 (m, 3H), 3.94-3.72 (m, 6H), 3.19-3.11 (m, 6H), 2.75-2.71 (m, 
6H), 1.49-1.27 (m, 18H) ppm. 
Table 2.3.2. Cyclization of sulfono-γ-AApeptides with varying ring sizes. 
compound ring size yielda (%) massb 
2-3-1 4 95 1073.3595 
2-3-2 2 90 537.1838 
2-3-3 3 85 805.2720 
2-3-4 5 85 1341.4466 
2-3-5 3 75 865.1080 
2-3-6 2 54 651.2999 
2-3-7 3 50 976.4464 
aYields were determined by analytical HPLC traces (Figure 2.3.8). b[M+1]+ determined by ESI. 
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Figure 2.3.9. Analytical HPLC traces for crude and purified sequences 2-3-1 to 2-3-7. 
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Crystallization study. 5 mg of 2-3-5 was dissolved in 500 μL chloroform. The solution was 
filtered through a 4 MM PVDF syringe filter (0.45 μm) and stored in a 2 mL vial, which was 
then covered with aluminum foil and placed in a sealed 20 mL vial containing 1 mL pentane. A 
block shaped crystal (dimension 0.3 mm x 0.3 mm x 0.2 mm) was obtained by pentane diffusion 
into the chloroform solution after 5 days at room temperature.  
The X-ray diffraction data was measured on a Bruker D8 Venture PHOTON 100 CMOS 
diffractometer equipped with a Cu Kα INCOATEC Imus micro-focus source (λ = 1.54178 Å). 
Indexing was performed using APEX2 (Difference Vectors method). Data integration and 
reduction were performed using SaintPlus 6.01. Absorption correction was performed by multi-
scan method implemented in SADABS. Space groups were determined using XPREP 
implemented in APEX2. The structure was solved using SHELXS-97 (direct methods) and refined 
using SHELXL-2013 (full-matrix least-squares on F2) contained in APEX2, WinGX v1.70.01 and 
OLEX2. All non-hydrogen atoms of the product were refined anisotropically. Hydrogen atoms of 
–CH, -NH, -CH2 and -CH3 groups were placed in geometrically calculated positions and included 
in the refinement process using riding model with isotropic thermal parameters: Uiso(H) = 
1.2(1.5)Ueq(-CH,-NH, -CH2(-CH3)). Occupancies of disordered chloroform molecules have been 
refined as free variables or were fixed. Heavily disordered molecules of chloroform and 
trifluoroacetic acid (presence confirmed by F NMR studies) have been refined using restraints and 
isotropically in case of atoms with low occupancy. Crystal data and refinement conditions are 
shown in Table 2.3.3. 
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Table 2.3.3 Crystal data and structure refinement for 2-3-5. 
Identification code 2-3-5 
Empirical formula C70.15H81.65Cl15.44F1.5N12O19S6 
Moiety formula 2(C33H39Cl3N6O9S3), 3.15(CHCl3), 0.5 (C2HO2F3)' 
Formula weight 2165.20 
Temperature/K 100(2) 
Crystal system orthorhombic 
Space group P212121 
a/Å 17.1143(4) 
b/Å 20.8803(6) 
c/Å 26.8416(6) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 9591.9(4) 
Z 4 
ρcalcg/cm3 1.499 
μ/mm-1 5.886 
F(000) 4442.0 
Crystal size/mm3 0.09 × 0.02 × 0.02 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 7.446 to 136.394 
Index ranges -20 ≤ h ≤ 20, -24 ≤ k ≤ 20, -32 ≤ l ≤ 32 
Reflections collected 50593 
Independent reflections 17264 [Rint = 0.0936, Rsigma = 0.1036] 
Data/restraints/parameters 17264/42/1169 
Goodness-of-fit on F2 1.016 
Final R indexes [I>=2σ (I)] R1 = 0.0677, wR2 = 0.1595 
Final R indexes [all data] R1 = 0.1073, wR2 = 0.1828 
Largest diff. peak/hole / e Å-3 0.55/-0.40 
Flack parameter 0.058(9) 
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Figure 2.3.10. (A) Overlay of 2-3-5 (red) with a turn region of a type II β turn (yellow) and (B) a 
turn region of a type I β turn (blue). 
Table 2.3.4 Dihedral angle measurement for 2-3-5. 
H
N
N
OR
R   
 
subunit      ω 
1 -154.7° 48.0° -134.7° 70.9° 174.9° 173.6° 
2 -83.2° 74.9° 99.8° -113.1° 6.0° -171.4° 
3 -142.3° -68.1° -86.8° 124.1° 3.5° -179.8° 
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CHAPTER 3: ONE-BEAD-ONE-COMPOUND (OBOC) γ-AAPEPTIDE LIBRARY 
 
 
Note to Reader 
 Contents in this chapter have been previously published in Chemical Communications, 
2014 50, 5206-5208, and have been reproduced with the permission of the Royal Society of 
Chemistry (RSC). 
3.1 Introduction 
One of the most important goals in modern chemical biology and biomedical sciences is 
to identify molecular ligands that recognize peptides or proteins of interest with high specificity 
and affinity.1 Combinatorial chemistry is a powerful approach for ligand screening as it creates a 
diverse library of compounds, which provides unbiased opportunity for ligand identification 
when the structural information of targets are not available or not helpful in the rational design.1 
In fact, most bioactive molecules are identified through screening efforts.2,3 As peptides have 
favorable protein binding capabilities and well-established synthetic protocol, early efforts were 
dedicated to the identification of selective peptide ligands against a variety of targets.4-7 
Unnatural peptidomimetic ligand libraries are of significant interest recently, as these ligands 
contain unnatural backbones and therefore possess enormous structural diversity and enhanced 
stability against proteolysis. The examples of peptidomimetic ligands include peptoids,1,8-13 β-
peptides,14 and N-acylated polyamine,15,16 etc. However, except for peptoids, the applications of 
peptidomimetic ligand libraries are rare. 
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-AApeptides are a new class of peptidomimetics developed in our lab very recently in 
order to advance the application of peptidomimetics in chemical biology and biomedical sciences 
(Figure 3.1a).17-24 As they contain N-acylated-N-aminoethyl amino acid units (Figure 3.1a) 
derived from γ-PNAs,25 they are termed “γ-AApeptides”.20 Each unit (building block) of the γ-
AApeptide is comparable to a dipeptide residue in a canonical peptide. As such, γ-AApeptides 
essentially project an identical number of functional groups as conventional peptides of the same 
length. Half of the side chains of γ-AApeptides are chiral, which may impose conformational 
bias to the molecular ligands similar to conventional peptides, and presumably lead to the 
identification of ligands with improved specificity and affinity.1 Since the other half of the side 
chains are introduced through acylation of the nitrogen on the backbone by carboxylic acids or 
acyl chlorides, there is virtually limitless potential of generating γ-AApeptide libraries with 
chemically diverse functional groups. Moreover, γ-AApeptides are highly resistant to proteolytic 
degradation,20,26 making them ideal candidates to be molecular probes or therapeutic candidates.  
To further expand the biological potential of γ-AApeptides, herein we report the 
development of γ-AApeptide OBOC library via the split-and-pool method. N-alloc protected γ-
AApeptide building blocks were used to prepare γ-AApeptides of diverse functional groups 
(Figure 3.1b and 3.1c).27  
3.2 Results and Discussion 
To find out if MS/MS could be potentially used to solve the unknown γ-AApeptide 
structure, we analyzed the fragmentation pattern of one known γ-AApeptide to prove that 
MS/MS is capable of determining the sequences of γ-AApeptides. As shown in Figure 3.2, this 
γ-AApeptide produces fragments in clear patterns and the sequence can be deduced 
unambiguously. 
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Figure 3.1. Synthesis of the γ-AApeptides. a, An -peptide and a -AApeptide. b, the synthesis 
of γ-AApeptides. c, N-Alloc protected γ-AApeptide building blocks and acylating agents 
(carboxylic acids and acyl chlorides) used in the preparation of γ-AApeptide combinatorial 
ligand library. 
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Figure 3.2. MS/MS analysis of a known γ-AApeptide. HCD fragmentation of a double charged 
precursor ion was performed at collision energy of 35.  
We then proceeded to the next step by establishing a one-bead-one-compound (OBOC) γ-
AApeptide library. The library was prepared by the split-and-pool method which produces beads 
with only one compound displayed on one bead (Figure 3.3).4 A methionine residue was first 
attached to the TentaGel beads (160002, 150 µm, 520, 000 beads/g), which facilitates the 
cleavage from beads by CNBr treatment.28 Then four N-alloc-protected γ-AApeptide building 
blocks and five acylating agents (including carboxylic acids or acid chlorides) (Figure 3.1c) were 
used to generate the combinatorial library of 4-building-block γ-AApeptides (comparable to 8-
mer peptides in length). In theory, this library would contain 4 x 5 x 4 x 5 x 4 x 5 x 4 x 6 = 
192,000 compounds.  
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Figure 3.3. Schematic representation of synthesizing OBOC γ-AApeptide library. 
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To explore the potential of this γ-AApeptide library as an excellent source of 
protein/peptide ligands, the library was screened against the Aβ40 peptide, which is one of the 
major etiological factors for Alzheimer’s disease (AD) and plays a central role in the 
pathogenesis of AD.29,30 Although it is of high significance to quickly identify novel anti-Aβ 
aggregation inhibitors, there is no effective approach to achieve it.31  
We hypothesized that the γ-AApeptide library can be used to identify ligands that bind to 
Aβ, and their anti-aggregation efficiency can be determined by functional assay afterwards. As 
such, we incubated beads with the Aβ40 peptide, followed by the treatment of anti-Aβ antibody 
6E10 (Figure 3.4a).  Then anti-mouse IgG-dylight 549 conjugate was added. Dylight 549 
produces strong orange fluorescence, in which region TentaGel beads have low background 
fluorescence.28 Out of ~192,000 beads, two putative hits (approximately 0.001% hit rate) were 
identified and collected. The low rate may suggest the high selectivity of the library. One of the 
structures was identified by MS/MS unambiguously (Figure 3.5). This lead, designated as HW-
155-1, was re-synthesized on Rink-amide resin (Figure 3.4b). The hydrophobic core residues 16-
20 of the Aβ peptide, KLVFF, which inhibits Aβ aggregation both in vitro and in vivo,32-35 was 
also synthesized and used for comparison.  
These two sequences were investigated for their capability to inhibit the aggregation of 
Aβ40 by ThT assay. Consistent to previous reports, KLVFF is a weak disruptor of Aβ aggregates. 
100 μM of KLVFF can only inhibit less than 50% of Aβ aggregation (Figure 3.6a). Surprisingly, 
1 μM of HW-155-1 already inhibits ~50% of Aβ aggregation (Figure 3.6b), indicating it is at 
least 100-fold more potent than KLVFF. The similar inhibitory effect was observed even after 24 
h (Figure 3.6c). As such, HW-155-1 is one of the most potent small molecules that disrupt the 
aggregation of Aβ40. 
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Figure 3.4. Screening of the γ-AApeptide library. a, Schematic representation of the on-bead 
screening of the γ-AApeptide library against the Aβ40 peptide. The last picture was taken under a 
fluorescent microscope installed with a triple filter pass. Excitation is 550 nm and emission is 
605 nm. b, the identified γ-AApeptide from the on-bead screening (HW-155-1) and the control 
peptide KLVFF. 
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Figure 3.5. Structural identification of one hit by MS/MS analysis. HCD fragmentation was 
performed on a double charged precursor ion (587.8827) and the collision energy was set at 35. 
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Figure 3.6. ThT assay of compounds against Aβ40. a, the change of fluorescence in the first 2 h 
of incubation of KLVFF with Aβ40; b, the change of fluorescence in the first 2 h of incubation of 
HW-155-1 with Aβ40; c, the ratio of aggregation after 24 h. Aggregation control (100%) is set as 
the change of fluorescence of 2.5 μM Aβ40 in Tris (pH 7.5) buffer. The concentration of ThT is 5 
μM. Excitation: 440 nm; emission: 482 nm. 
The ability of HW-155-1 to prevent Aβ aggregation was further confirmed by TEM 
(Figure 3.7a and 3.7b). In fact, HW-155-1 can even disassemble pre-formed Aβ fibrils (Figure 
3.7c and 3.7d). In our experiments, the Aβ fibrils were not seen after incubating HW-155-1 with 
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Aβ40 monomers (prevention of aggregation) and pre-formed Aβ40 aggregates (disassembling 
aggregation) for 24 h. 
 
Figure 3.7. TEM images. Monomeric Aβ40 in the absence (a) and presence (b) of HW-155-1 
after 24 h; and pre-aggregated Aβ40 in the absence (c) and presence (d) of HW-155-1 after 24 h. 
bar = 1 μM. Aβ40 is 2.5 μM and HW-155-1 is 5 μM. 
We then examined the effect of HW-155-1 on the toxicity of Aβ aggregates towards N2a 
neuroblastoma cells. In this cellular assay, Aβ42 was chosen as Aβ42 aggregates are easier to form 
and are more toxic than Aβ40 aggregates towards neural cells.33,36 As shown in Figure 3.8, 
aggregated Aβ42 kills 30% of N2a cells after 24 h incubation. In contrast, addition of 0.5 equiv. 
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of HW-155-1 already reduces the death of N2a cells caused by Aβ42 to 25%, while the presence 
of 1 equiv. HW-155-1 virtually completely removes the toxicity of Aβ42 and eliminates the death 
of N2a cells. The capability of HW-155-1 to rescue these neuroblastoma cells suggests that HW-
155-1 may prevent the formation of Aβ aggregates and thus decrease the Aβ toxicities. 
 
Figure 3.8. Detoxification of Aβ42 aggregates by HW-155-1. N2a cells were cultured with 1 µM 
of pre-aggregated Aβ42 in the absence/presence of HW-155-1 for 24 h. 
3.3 Conclusions 
In summary, we have developed a new class of peptidomimetic combinatorial library that 
shows great promise to be a rich source of protein/peptide ligands. γ-AApeptides have the unique 
backbone that allows introduction of diverse functional groups with limitless potential. Their 
similarity in size and chirality to canonical peptides also confers favorable characteristics to bind 
and interact with other peptides and proteins. Our initial effort with this novel library has led to 
the identification of a lead small γ-AApeptide that is 100-fold more effective than KLVFF to 
prevent and even disassemble Aβ aggregation, and removes the toxicity of Aβ aggregates 
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towards N2a neuroblastoma cells. Such a compound may be used as the potential molecular 
probe or therapeutic agent for the treatment of Alzheimer’s disease (AD). We are currently 
working on the development of new γ-AApeptide on-bead libraries with novel functional 
diversities so as to discover new bioactive candidates for biomedical applications, as well as the 
optimization of the lead γ-AApeptide HW-155-1 for the intervention of AD. 
3.4 Experimental Section 
General information. All Fmoc protected α-amino acids and Rink amide resin (0.7 mmol/g, 
200-400 mesh) were purchased from Chem-Impex International, Inc. TentaGel MB NH2 resin 
(0.3 mmol/g, 140-170 µm) was purchased from RaPP Polymere GmbH. All the other solvents 
and reagents were purchased from either Sigma-Aldrich or Fisher Scientific. NMR data for 
building blocks was obtained on a Varian UnityInova400 spectrometer. High resolution masses 
of building blocks were determined on an Agilent 6540 Liquid Chromatography/Quadrupole 
Time-of Flight mass spectrometer. Masses of γ-AApeptides were obtained on an Applied 
Biosystems 4700 Proteomics Analyzer. MS/MS analysis was carried out with a Thermo LTQ 
Orbitrap XL. Solid phase synthesis was conducted in peptide synthesis vessels on a Burrell 
Wrist-Action shaker. γ-AApeptides were analyzed and purified on a Waters Breeze 2 HPLC 
system, and then lyophilized on a Labcono lyophilizer. 
The amyloid beta peptide Aβ40 was used as a target for the combinatorial library screen 
because insoluble Aβ plaque was thought to be a pathological marker in Alzheimer’s disease 
(AD).37 The synthesized library was stored in a glass peptide synthesis vessel, and later washed 
and incubated in the same container. The antibodies were purchased from Fisher Scientific, and 
all the other chemical were provided by Sigma-Aldrich. The beads were screened and picked up 
under Zeiss inverted fluorescence microscope 10x43HE filter. 
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Solid phase synthesis of γ-AApeptides. 
 
Figure 3.9. Solid phase γ-AApeptide synthesis.  
Solid phase synthesis was conducted on Rink amide resin (0.7 mmol/g) in peptide 
synthesis vessels on a Burrell Wrist-Action shaker (Figure 3.9). 100 mg resin (0.07 mmol) was 
treated with 3 mL 20% Piperidine/DMF solution for 15 min (× 2) to remove Fmoc protecting 
group. The solution was drained and beads were washed with DCM (3 × 3 mL) and DMF (3 × 
3mL). A solution of γ-AApeptide building block (2 equiv.),17,19,20,22,38 HOBt (38 mg, 0.28 
mmol), and DIC (44 µL, 0.28 mmol) in 3 mL DMF was shaken for 5 min, and then added to the 
resin in a peptide synthesis vessel. The mixture was allowed to react at room temperature for 6 h 
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and drained. The beads were washed with DCM (3 × 3 mL) and DMF (3 × 3 mL), followed by a 
capping reaction with 500 µL acetic anhydride in 3 mL Pyridine. After washing with DMF (3 × 
3 mL) and DCM (3 × 3 mL), to the beads were added Pd(PPh3)4 (8 mg, 0.007 mmol)  and 
Me2NH·BH3 (25 mg, 0.42 mmol) in 3 mL DCM. 39 The alloc deprotection reaction was shaken 
for 10 min and repeated one more time. The beads were washed with DCM and DMF, followed 
by the reaction with acid chloride (4 equiv.) and DIPEA (6 equiv.) in 3 mL DCM for 30 min (× 
2) or with carboxylic acid (4 equiv.), HOBt (8 equiv.), and DIC (8 equiv.) for 4 h (× 2). 
The previous steps were repeated until the desired sequences were obtained. After that, 
the resin were washed with DCM and dried in vacuo. Peptide cleavage was done in a 4 mL vial 
by treating resin with TFA/H2O/TIS (95/2.5/2.5) for 2 h. The solvent was evaporated and the 
crude was analyzed and purified on an analytical (1 mL/min) and a preparative (20 mL/min) 
Waters HPLC systems, respectively. 5% to 100% linear gradient of solvent B (0.1% TFA in 
acetonitrile) in A (0.1% TFA in water) over 40 min was used. The HPLC traces were detected at 
215 nm. The products were confirmed on an Applied Biosystems 4700 Proteomics Analyzer. 
Then, the desired fractions were collected and lyophilized. 
MS/MS analysis. The fragmentation pattern of a known γ-AApeptide was analyzed on a Thermo 
Scientific LTQ Orbitrap XL mass spectrometer (Figure 3.2). Higher Energy Collision 
Dissociation (HCD) was performed at collision energy of 35. 
Synthesis of the OBOC γ-AApeptide library. The TentaGel NH2 resin (1.6 g, 0.48 mmol, 
832,000 beads) was swelled in DMF for 1h, followed by the treatment with Fmoc-Met-OH (3 
equiv.), HOBt (6 equiv.), and DIC (6 equiv.) in DMF.10 The beads were shaken at room 
temperature in a peptide synthesis vessel for 4 h and repeated. The beads were washed with 
DCM (× 3) and DMF (× 3). Fmoc protecting group was removed with 20% piperidine in DMF 
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for 20 min (× 2). The beads were washed and equally distributed into four peptide synthesis 
vessels. Each building block (2 equiv.) together with HOBt (4 equiv.) and DIC (4 equiv.) were 
dissolved in DMF and added to each vessel. The coupling reaction was performed at room 
temperature for 6 h and repeated. The beads in each vessel were then washed and mixed 
thoroughly by severe shaking for 1 h. The beads were equally split into five vessels. The Alloc 
protecting group was removed by treating beads with Pd(PPh3)4 (0.1 equiv.) and Me2NH·BH3 (6 
equiv.) in DCM for 10 min (× 2). After washing, each portion was reacted with either acid 
chloride or carboxylic acid. The reaction with acid chloride (5 equiv.) was carried out in the 
presence of DIPEA (5 equiv.) and DCM for 30 min (× 2). The carboxylic acids (3 equiv.) were 
pre-activated with DIC (6 equiv.) and HOBt (6 equiv.) in DMF, then added to beads. The 
reaction was carried out by shaking the vessel for 6 hours and repeated. After that, all the beads 
were pooled and mixed thoroughly. The previous split-and-pool process was repeated three 
times. The last time, after attachment of building blocks, beads were equally distributed into six 
portions, five of which were treated with alloc deprotection reagents then with acid chlorides and 
carboxylic acids as shown previously. The sixth portion was kept unreacted. At last, all beads 
were combined in one peptide synthesis vessel and washed thoroughly with DMF and DCM. 
Beads were treated with 20% piperidine in DMF for 20 min (× 2) and then with TFA/TIS/H2O 
(95:2.5:2.5) for 2 h to remove all the protecting groups. The beads were washed with DCM 
thoroughly and dried in vacuo. 
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Figure 3.10. Schematic representation of synthesizing OBOC γ-AApeptide library. 
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Beads screening. The library synthesized on TentaGel beads was swelled in dimethylformamide 
(DMF) for 1 hour, washed with 1×TBST for five times and then equilibrated in 1×TBST 
overnight at room temperature. 28 The beads were blocked in 1% BSA in TBST for 1 hour, 
washed and equilibrated in 1×PBST before prescreening and screening. 
Prescreening: In order to avoid any possible nonspecific binding, both the Aβ and 
antibodies olution were made in 1% BSA/TBST blocking buffer. The library was first incubated 
with mouse 6e10 primary antibody (200 ng/mL) which recognizes the first 16 amino acids of 
Aβ1-40, followed by five times PBST wash and incubation with goat anti-mouse IgG conjugated 
with dylight 549 (200 ng/ml). The beads were washed with PBST completely and transferred 
into a 6-well plate to be observed under Zeiss inverted fluorescence microscope 10×43HE filter, 
and the orange bright beads were picked up for they had suspicious nonspecific binding. These 
bright beads were excluded for further screening. 
The rest of the beads were pooled together, washed with PBST, and then treated with 1% 
SDS at 90 oC for ten minutes to remove any bound proteins. We used both water and TBST to 
wash away the SDS and then the beads were washed and swelled in DMF for 1 hour. After 
washing and equilibrating in TBST overnight, the beads were ready for actual Aβ screening. 
Screening: The prescreened beads were equilibrated in 1% BSA/PBST for 1 hour at room 
temperature. Aβ solution was made by dissolving Aβ40 powder in the buffer right before the 
screening. After washing with PBST for three times, the beads were incubated with Aβ40 peptide 
at a concentration of 20 µg/mL for 4 h at room temperature. Since Aβ40 aggregates quite slowly 
and the screening was done in such as short time, the percentage of Aβ40 aggregation in the 
solution was very minimal. After thorough washing with PBST, the library beads were incubated 
in 5 mL of 1% BSA/PBST containing 1:5000 diluted mouse 6e10 antibodies for 2 hours at room 
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temperature. The beads were gently washed with PBST and incubated with 1:500 diluted goat 
anti-mouse IgG-dylight 549 for 1 hour at room temperature. The beads were washed with PBST 
and transferred into the 6-well plate to be observed under Zeiss inverted fluorescence microscope 
10×43HE filter. Again the bright orange ones were picked up as candidates for further study. 
Sequence decoding. The beads were collected and washed with 1×PBST three times. The bound 
fluorescent dyes, proteins, and antibodies were removed by treating beads with 1% SDS solution 
at 90 °C for 10 min. After being washed with water, DMSO, and acetonitrile, beads were then 
cleaved and analyzed using previous procedure. The structure of one hit was determined (Figure 
3.5) and designated as HW-155-1. 
Solid phase synthesis of HW-155-1 and KLVFF peptide. HW-155-1 was resynthesized on 
rink amide resin following previous procedure. (Figure 3.9) The mass was determined to be 
1091.1375 (M+H)+ on an Applied Biosystems 4700 Proteomics Analyzer. The purity was 
analyzed on an analytical Waters HPLC system with flow rate of 0.8 mL/min and linear gradient 
from 5% to 100% (CH3CN in water) in 40 min (Figure 3.11a). As a positive control, KLVFF 
sequence was synthesized manually using regular solid phase peptide synthesis method. Amino 
acids were assembled on rink amide resin individually using HOBt/DIC as coupling reagents. 
After cleavage with TFA/TIS/H2O (95:2.5:2.5) for 3 h, TFA was removed under reduced 
pressure. The peptide was purified and analyzed on a preparative and analytical Waters HPLC 
system, respectively. (Figure 3.11b) 
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Figure 3.11. HPLC traces of pure compounds HW-155-1 (a) and KLVFF peptide (b).  
Thioflavin T (ThT) assay. Compounds in different concentrations in Tris buffer Saline (TBS, 
pH 7.5) containing 10 µM ThT were added into a black 96 well plate corning@3721. Aβ40 
monomer was freshly thaw and used to make a stock solution in TBS with a concentration of 5 
µM. Equal volume of Aβ solution was added into the 96 well plate (Final Aβ conc. = 2.5 µM). 
Time-dependent fluorescence change was monitored by a Synergy 2 plate reader at an excitation 
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wavelength of 440 nm and emission at 482 nm. After 24 h, the fluorescence change was 
recorded. 100% aggregation is the fluorescence change of 2.5 μM Aβ40 in TBS buffer containing 
5 µM ThT. 
Transmission electron microscopy (TEM). Aβ40 preparations were adsorbed onto 200-mesh 
copper grids for 1 hour (until it is dry), and then stained with 1% uranyl acetate for 20 sec. The 
excess fluid was removed and the grids were analyzed with FEI Morgagni 268D TEM operated 
at 60 kV. 
MTT toxicity assay. In siliconized tubes, Aβ42 peptide of 10 µM (in F-12 medium) was pre-
incubated with 0, 0.5 and 1 equiv. of HW-155-1 γ-AApeptide, respectively. These solutions 
were incubated on a rotating shaker (Barnstead 400100) at 8 rpm in 37 oC for 24 h.  Meanwhile, 
N2a cells were plated in 96-well plates (10000 cells/well) with three replicates for 24 h at 37 oC. 
Then pre-aggregated mixtures were added into each well to make the final Aβ concentration 1 
µM. The plate was incubated for another 24 h at 37 oC. Next, 10 µL MTT reagent was added to 
the cells.  The plate was incubated for 4 h at 37 oC. After the addition of 100 µL solublization 
solution (10% Triton-X 100 in acidic Isopropanol (0.1N HCl)) and incubation for overnight, OD 
values were read at 575 nm. The final cell viability was calculated as: 
Cell viability % = (OD575-ODblank)/(ODctrl – ODblank) x 100%. ODctrl is the OD of the well 
containing cells only. ODblank is the OD of the blank well.  
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CHAPTER 4: SULFONO-γ-AAPEPTIDES AS A NEW CLASS OF UNNATURAL 
HELICAL FOLDAMER 
 
 
Note to Reader 
Contents in this chapter have been previously published in Chemistry A European 
Journal, 21(6), 2501-2507 and have been reproduced with the permission of the John Wiley and 
Sons. 
4.1 Introduction 
Natural biopolymers including proteins and nucleic acids adopt well-defined and compact 
three-dimensional folding conformations providing a structural basis for their complex biological 
functions.1 This paradigm suggests that unnatural foldamers with new molecular frameworks and 
folding propensities may also exhibit unique biomimetic properties that can be exploited in 
pharmaceutical development and advanced biotechnology applications.2 Specifically, unnatural 
foldamers offer opportunities to better understand biomolecular structure-function relationships, 
facilitate the design of novel nanostructures, and develop targeted diagnostic agents and potential 
drug candidates.3 Since unnatural monomers have an enormous diversity in size, shape and 
backbone structure, unnatural foldamers can theoretically be developed to display a wide variety 
of three-dimensional conformations and biomimetic function.4-7 In addition, many unnatural 
foldamers are resistant to proteolytic degradation, augmenting their potential application in 
biological systems. The potential importance of unnatural foldamers has led to the development 
of numerous foldamer systems including β-peptides,8-10 α-aminoxy-peptides,11 peptoids,12 and 
oligoureas.13,14 However, unnatural foldamers have just recently begun to find biological 
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applications and thus the  continued development of new building blocks, molecular frame works 
and backbones are of key interest. 
We recently have developed a new class of peptidomimetics - γ-AApeptides, oligomers 
of N-acylated-N-aminoethyl amino acids (Figure 4.1).15 As half of the side chains are introduced 
through acylation, γ-AApeptides have virtually limitless potential in functional group diversity. 
Although γ-AApeptides are based upon a chiral PNA backbone,16 they are designed to capture 
the function of bioactive peptides rather than nucleic acids.17,18 For instance, certain γ-
AApeptides display both antimicrobial activity19-21 and anti-inflammatory activity22 by 
mimicking host-defense peptides while others mimic the Tat peptide by binding to HIV-1 RNA 
with high affinity18 and permeating cell membranes with excellent efficiency.17 In addition, γ-
AApeptides have been developed to mimic the RGD peptide23 and to form one-bead-one-
compound libraries for the discovery of bioactive protein/peptide based ligands.24,25 Furthermore, 
γ-AApeptides can also form novel nanostructures akin to peptide-based biomaterials.26 The 
emerging importance of γ-AApeptides has heightened the interest in the folding propensity 
regarding biomolecular structure. 
 
Figure 4.1. The general chemical structures of α-peptides, γ-AApeptides and sulfono-γ-
AApeptides. 
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4.2 Results and Discussion 
 One of the most attractive features of γ-AApeptides is that half of the side chains do not 
have to be derived from carboxylic acids. As shown in Figure 4.1, replacement of carboxylic 
acids with sulfonyl chlorides leads to the generation of sulfono-γ-AApeptides.27 As a subclass of 
γ-AApeptides, sulfono-γ-AApeptides possess essentially unlimited functional diversity, as a 
wide variety of functionalized sulfonyl chlorides are either available commercially or can be 
readily synthesized.28,29 Moreover, Sulfono-γ-AApeptides contain the same number of side 
chains as regular peptides of the same lengths, affording the potential of sulfono-γ-AApeptides to 
mimic bioactive peptides. The presence of protons in the second amide moieties in sulfono-γ-
AApeptides indicate these polymers may exhibit folding propensities through intramolecular 
hydrogen bonding akin to α-peptides. In addition, the tertiary sulfonamido moieties are 
sufficiently bulky as to induce intrinsic curvature into the sulfono-γ-AApeptide backbone. 
Furthermore, half of side chains of sulfono-γ-AApeptides are chiral, which may also impose 
conformational bias to further promote the formation of specific secondary conformation. 
To test the hypothesis that sulfono-γ-AApeptide foldamers can form discrete secondary 
structures, we have synthesized a series of sulfono-γ-AApeptides of differing lengths. The 
longest sulfono-γ-AApeptide (4-1) contains eight building blocks, comparable in length to a 16-
mer peptide. The shortest sequences 4-5 and 4-6 are sulfono-γ-AApeptide monomers which are 
equivalent to dipeptides (Figure 4.2).  
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Figure 4.2. The chemical structures of the sulfono-γ-AApeptides 4-1 to 4-6. In each sulfono-γ-
AApeptide, the residues from the N-terminus are numbered as 1, 2, etc. In each sulfono-γ-
AApeptide residue, a denotes the chiral side chain derived from the cognate α-amino acid, and b 
represents the sulfonyl side group coming from sulfonyl chlorides. 
The sulfono-γ-AApeptides 4-1 to 4-5 were obtained through solid-phase synthesis 
following our previously published protocol (Figure 4.3).24,27 In brief, the desired N-alloc γ-
AApeptide residues24,27 were attached sequentially on the solid support. After each N-alloc γ-
AApeptide residue was added, the alloc protecting group was removed with 10 mol % equiv. of 
Pd(PPh3)4 and 6 equiv. of Me2NH·BH3 in DCM.30 Subsequently, the sulfonyl side group was 
introduced by reacting a sulfonyl chloride with the secondary nitrogen on the γ-AApeptide 
backbone. The synthetic cycle was repeated until the desired sequence was assembled followed 
by cleavage and purification by HPLC. The monomers were prepared as previously reported.24,27 
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Figure 4.3. Synthesis of the sulfono-γ-AApeptides 4-1 to 4-5. 
The crystal structure of the monomer 4-6 was successfully obtained and shown in Figure 
4.4a. The crystal structure indicates that the 4-6 adopts a right-handed turn conformation. 
Consistent with our hypothesis, the bulky tertiary sulfonamido group appears to force the 
formation of the backbone curvature. In addition, there is a hydrogen bond formation between 
NH of N-termini and CO of C-termini. An overlay of 4-6 with a canonical α-helical scaffold 
reveals that this turn curvature matches that of the α-helical sense (Figure 4.4b). The 
demonstration that such a short sulfono-γ-AApeptide has a defined pre-organized structure due 
to the intrinsic folding propensity leads to the possibility that longer sulfono-γ-AApeptides can 
be formed with more defined and stable secondary structures. 
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Figure 4.4. a Crystal structure of the sulfono-γ-AApeptide monomer 4-6. b, Overlay of 4-6 on 
an α-helical polyalanine scaffold.  
We have then carried out NMR studies of the longest sequence, 4-1. In order to solve the 
structure unambiguously, different hydrophobic and hydrophilic groups are included in in the 4-1 
sequence. The NMR spectra were collected on an Agilent dd600 with a triple resonance cold 
probe. The 1D 1H NMR spectra were first obtained with differing concentrations (0.05-1 mM) 
and the chemical shifts of the backbone protons were compared. There were no obvious changes 
in the chemical shifts, suggesting that 4-1 does not aggregate under the experimental conditions 
(Figure 4.5). Next, 2D NMR was employed to investigate the solution structure of 4-1 in 
methanol (2 mM in CD3OH, 10 ºC). Two-dimensional spectra (zTOCSY, NOESY) were 
collected using standard pulse sequences with the number of acquisitions typically set to 200 for 
the NOESY and 6 for the zTOCSY spectra. The Water suppression through Enhanced T1 Effects 
(WET) method was used to suppress the proton peak in the CD3OH solvent. In general, a 2s 
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delay was applied before each scan. Experiments were collected with 2K complex data points in 
F2 for each of 300 t1 increments with a sweep width of 6009 Hz in each dimension. Residue-
specific assignments were made based on a combination of DQFCOSY, zTOCSY, ROESY and 
NOESY spectra. The presence of different side chains eliminates the potential overlaps between 
proton signals and are helpful for the unambiguous assignment of different building blocks. The 
CαHs were successfully assigned based on the short-range and/or sequential NOEs with 
neighbor side chains or amide proton (Figure 4.6).  
Medium/long range NOEs revealed clear i–i+3 correlations between related side chains, 
i.e., 1bHPA-3aHB, 2aHB-3bHPA, 3bHPA-5aHB, 4aHG-5bHPA, 5bHPE-7aHB, 6aHγ-7bHPA 
(Figure 4.7). The i-i+3 correlation pattern implies that there is a defined folding pattern in 4-1, 
which displays proximity between every first and third building blocks. 
 
Figure 4.5. 1H NMR spectra of 4-1 in CD3OH at different concentrations (0.05, 0.1 and 1 mM). 
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Figure 4.6. (a) Typical sequential NOEs observed for 4-1. Residue numbers are labeled. (b) 
Corresponding peaks in NOE spectrum. 
The NMR solution structure was solved and is displayed in Figure 4.8. Schrödinger 
Macromodel31 was used to perform molecular dynamics calculations based upon the NOE 
constraints, which resulted in the 10 best structures. As shown in Figure 4.8b, the structures 
display very good overlap among backbone atoms (rmsd = 0.72 ± 0.29 Å, Figure 4.8b and 
Table 4.4). The average of the 10 helical structures for 4-1 is also displayed in Figure 4.8c and 
4.8d. The data demonstrate that 4-1 adopts a well-defined right-handed helical conformation in 
methanol, with the side chains pointing away from the helical scaffold. Further analysis of the 
structure of 4-1 reveals a helical radius (2.3 Å) that is the equivalent to the canonical α-helix. In 
addition, the average of helical pitches is 5.7 Å, which is also very close to that of the peptide 
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based α-helix (5.4 Å). Furthermore, the structure indicates that each turn contains four side 
chains (Figure 4.8e), relative to 3.6 residues/turn found in α-helical peptides. This assignment is 
also consistent to the observation of i-i+3 NOE patterns. These features suggest that the sulfono-
γ-AApeptide could be developed to mimic the structure and function of α-helices. 
The NMR structure further suggests that 4-1 has a 10/16 helix hydrogen-bonding pattern (Figure 
4.9). It is known that the α-helix is the 13-helix; however, the same hydrogen pattern cannot be 
formed in sulfono-γ-AApeptides due to an alternative secondary amide and tertiary sulfonamide 
functionalities. Nonetheless, each 10/16 helix cycle in a sulfono-γ-AApeptide is equivalent to 
two successive 13-helices in the α-helix. This feature may partially explain why the helical pitch 
and the radius of 4-1 are similar to those of the α-helix. Additionally, as expected, sulfonyl 
groups also contribute to the stability of the helical structure by directly participating in hydrogen 
bonding. SO2 groups (except the first and last one) point away from the helical scaffold and do 
not participate in hydrogen bonding. 
Circular Dichroism (CD) spectroscopy can also provide an assessment of the folding 
propensity of oligomers including proteins, peptides as well as unnatural molecules such as β-
peptides and peptoids. The CD spectra of 4-1 under different solvent conditions in displayed in 
Figure 4.10a. The spectra exhibit a maximum at ~220 nm. Interestingly, it appears that the 
sequence adopts a more stable helical conformation in PBS buffer relative to TFE, suggesting the 
potential of sulfono-γ-AApeptide for the mimicry of the α-helix and modulation of protein 
interactions in biological systems. The CD data further indicate that the sequence is not 
aggregated under the concentration range examined here, as a 10-fold dilution in TFE has little 
or no effect on the spectrum.  
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Figure 4.7. Typical medium or long range NOEs showing i-i+3 correlations in 4-1. Residue 
numbers are labeled. i stands for side chains. 
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Figure 4.8. (a) The chemical structure of the sulfono-γ-AApeptide 4-1, as well as non-sequential 
NOEs indicated by curved lines; (b) Overlay of the ten lowest energy three-dimensional 
structures of 4-1 with lowest energies calculated based on NOE constraints (2D NMR were 
carried out in CD3OH at 10 °C) and using MD simulations; (c) The average structure based upon 
b; (d) A helical ribbon is drawn to guide the review; (e) Approximate positions of side chains on 
the helical scaffold. Residue 1, which is less ordered in solution, is omitted. 
 
Figure 4.9. Possible hydrogen bonding pattern suggested by the average of the 10 best structures 
of 4-1 generated via NOE-restrained molecular dynamics. The numbers indicate the number of 
atoms in the hydrogen-bonded rings, respectively. 
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The stability of the helix was further examined by temperature-dependent CD analysis 
(Figure 4.10b). As expected, 4-1 forms more defined helical structures at low temperatures. 
However, the secondary folding structure is still discernable even up to 55 °C. To assess the 
general folding propensity of sulfono-γ-AApeptides, CD analysis was also carried out for the 4-2 
to 4-5 sulfono-γ-AApeptide sequences. As shown in Figure 4.10c, even the shortest sequence 4-5 
displayed some degree of helicity, which is consistent to the crystal structure of 4-6 foldamer. 
The clear trend is that longer sequences form better helical structures. The 4-4 is a trimer 
sequence that displays increased helicity relative to 4-5. This is similar to the helical propensity 
of α-peptides. Additionally, the bulky group appears to stabilize the helical conformation, as 
observed with another trimer sequence 4-3, which contains an aromatic group and exhibits much 
more discernable helicity than 4-4. Surprisingly, the pentamer sequence 4-2, which is 
comparable to a decamer peptide, displays almost identical helicity to the longest sequence 4-1. 
This indicates that the general helical propensity of sulfono-γ-AApeptides is quite high. 
However, as our peptidomimetics do not have canonical peptide backbone, CD data is just used 
as the supporting data for NMR structures, and should not be overly interpreted. For example, 
the dichroic bands from the arylsulfonamido chromophores may have the potentially overlapping 
and disrupting role. In addition, the cotton effect near 220 nm may not be the accurate indication 
of molecular helicity.  
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Figure 4.10. a, CD spectra of 4-11 in different solutions at 25 °C. (1) in methanol, 200 µM; (2) 
in 1:1 methanol/H2O, 200 µM; (3) in 1:1 methanol/TFE, 200 µM; (4) in 1:1 methanol/TFE, 20 
µM. b, CD spectra of 4-1 at various temperatures in methanol. c, CD spectra of 4-1 to 4-5 (200 
µM) in methanol at 25 °C.  
4.3 Conclusions 
In summary, we have identified a new class of unnatural helical foldamer- sulfono-γ-
AApeptides. The crystal structure indicates that even the shortest sulfono-γ-AApeptide 
(monomer) possesses a pre-organized folding structure. NMR studies further suggest that 
sulfono-γ-AApeptides adopt well-defined right-handed helical conformations in solution similar 
to peptide based α-helices. Similar to α-peptides, the sulfono-γ-AApeptide 4-1 is also stabilized 
by intramolecular hydrogen bonding. CD studies suggest that the similar folding propensity is 
generally observed throughout the sulfono-γ-AApeptide library examined here, and longer 
sequences exhibit more pronounced helicity in their secondary structures. As a virtually endless 
set of functional groups can be incorporated into sulfono-γ-AApeptides, the folding propensity 
can be further programmed by a number of chemical approaches including inclusion of 
constrained residues 32 and hydrocarbon stapling,33 we envision that sulfono-γ-AApeptide 
foldamers can be readily developed to address a variety of challenges in chemical biology. 
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4.4 Experimental Section 
General information. All Fmoc protected α-amino acids and Rink-amide resin (0.7 mmol/g, 
200-400 mesh) were purchased from Chem-Impex International, Inc. All the other solvents and 
reagents were purchased from either Sigma-Aldrich or Fisher Scientific and used without further 
purification. Solid-phase synthesis of sulfono-γ-AApeptides were conducted in a peptide 
synthesis vessel on a Burrell Wrist-Action shaker. The sulfono-γ-AApeptides were analyzed and 
purified on a Waters Breeze 2 HPLC system, and then lyophilized on a Labcono lyophilizer.  
The molecular weight of sulfono-γ-AApeptide was obtained on an Applied Biosystems 4700 
Proteomics Analyzer. All NMR experiments were performed at 10 °C on a Varian VNMRS 600 
MHz spectrometer equipped with four RF channels and a Z-axis-pulse-field gradient cold probe. 
Synthesis and characterization of sulfono-γ-AApeptides.24,27 Synthesis of the sequence 4-1: 
Solid-phase synthesis was carried out on 100 mg Rink-amide resin (0.7 mmol/g) at room 
temperature. The resin was swelled in DMF for 1 h before use. The Fmoc protecting group was 
removed by treating the resin with 3 mL 20% piperidine/DMF solution for 15 min (x2). The 
resin was washed with DCM (x3) and DMF (x3). A premixed solution of N-alloc γ-AApeptide 
building block24 (3 equiv.), HOBt (6 equiv.), and DIC (6 equiv.) in 2 mL DMF was added to the 
resin. The mixture was shaken for 4 h. After being washed with DCM and DMF, the resin was 
treated with Pd(PPh3)4 (8 mg, 0.007 mmol) and Me2NH·BH3 (25 mg, 0.42 mmol) in 3 mL DCM 
for 10 min (x2), then reacted with the desired sulfonyl chloride (4 equiv.) and DIPEA (6 equiv.) 
in 3 mL DCM for 30 min (x2). The reaction cycles were repeated until the desired sequence was 
assembled on the solid phase. After that, the resin was washed with DCM and dried in vacuo. 
The sulfono-γ-AApeptide cleavage was achieved in a 4 mL vial by treating the resin with 
TFA/H2O/TIS (95/2.5/2.5) for 2 h. The solvent was evaporated and the crude was analyzed and 
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purified on an analytical (1 mL/min) and a preparative (16 mL/min) Waters HPLC systems, 
respectively. 5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile) in A (0.1% 
TFA in water) over 40 min was used. The HPLC trace was detected at 215 nm. The desired 
fraction was collected and lyophilized, and confirmed on an Applied Biosystems 4700 
Proteomics Analyzer. Then, the desired fraction was lyophilized. 
Other sequences: 4-2 to 4-5 were synthesized using the same synthetic protocol as 4-1. 
The masses of these sequences are as follows: 
4-1: theoretical: 2058.7, found: 2059.6 ([M + H]+), (MALDI). 
4-2: theoretical: 1406.5, found: 1407.9 ([M + H]+), (MALDI). 
4-3: theoretical: 711.4, found: 712.1 ([M + H]+), (ESI). 
4-4: theoretical: 635.2, found: 636.1 ([M + H]+), (ESI). 
4-5: theoretical: 251.1, found: 252.0 ([M + H]+), (ESI). 
4-6: theoretical: 508.2, found: 506.1 ([M + H]+), (ESI). 
2D NMR analysis of sulfono-γ-AApeptide 4-1.The sulfono-γ-AApeptide 4-1 was dissolved in 
approximately 0.5 mL of CD3OH in a 5 mm NMR tube. The 1H shift assignment was achieved 
by sequential assignment procedures based on zTOCSY and NOESY measurement. TOCSY and 
NOESY spectra were acquired with the wet solvent suppression. All these experiments were 
performed by collecting 6009 points in f2 and 300 points in f1. A DIPSI2 spin lock sequence 
with a spin lock field of 6k Hz and mixing time of 80 ms were used in zTOCSY. NOESY 
experiment used a mixing time of 200 ms. Vnmrj was used to process the data and 2D NMR 
spectra were analyzed by using SPARKY program. 
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Figure 4.11. Analytical HPLC traces of the purified sulfono-γ-AA peptides 4-1 to 4-5. 
 
Figure 4.12. 1H NMR of 4-1 in CD3OH at 10 °C. 
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Figure 4.13. (Continued) 
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Figure 4.13. (Continued) 
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Figure 4.13. (Continued) 
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Figure 4.13. (Continued) 
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Figure 4.13. (Continued) 
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Figure 4.13. Overlay of 2D NMR spectra in CD3OH at 10 °C (green: NOESY, red: zTOCSY). 
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Table 4.1 Labeling names used in 2D NMR assignment (chemical shifts of protons on the 
backbone). See structure below for designations of α, β, γ carbons. a and b denote the chiral side 
chain and the sulfonyl group from a sulfono-γ-AApeptide building block, respectively. 
 
 
Residue HN 1H-α 1H-β 1H-γ 
0  1.825   
1 7.892 3.776 2.885 4.173 
  4.025 3.149  
2 7.988 3.964 3.251 4.195 
  4.203 3.321  
3 8.028 2.861 2.840 4.333 
  4.020 2.277  
4 8.099 3.855 3.202 4.329 
  4.079 3.281  
5 8.010 3.737 2.760 4.131 
  4.043 3.270  
6 8.285 3.716 3.278 4.322 
  4.034 3.323  
7 8.178 3.708 2.826 4.194 
  3.964 3.236  
8 8.362 3.936 3.207 4.136 
  3.963 3.277  
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Figure 4.14. Sequential NOE data for 4-1 in CD3OH at 10 °C.  
Molecular dynamics (MD) calculations based on NOEs. NOE-constrained molecular 
dynamics calculations were carried out by using MacroModel.34 Based on signal intensities, 
NOEs observed for the sulfono-γ-AApeptide S1 were grouped into one of four categories, 
1.7~2.5 Å, 2.5~3.5 Å, 3.5~4.5 Å, 4.5~5.5 Å. 10 best structures were identified from the MD 
process employing the NOE constraints. 
Table 4.2 List of sequential NOEs. 
 
Residue H-atom Residue H-atom Restraints(Å) 
0 Hα 1a HN 3.5-4.5 
1a HB 1b HPA 2.5-3.5 
1a HB 1b HPB 4.5-5.5 
1a Hβ1 1b HPA 2.5-3.5 
1a Hβ2 1b HPA 2.5-3.5 
1a Hβ1 1b Hα1 1.0-1.7 
1a HB 1b Hα1 2.5-3.5 
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Table 4.2 (Continued) 
1b Hα1 2a HN 1.7-2.5 
1b Hα2 2a HN 2.5-3.5 
2b Hα1 3a HN 2.5-3.5 
2b Hα2 3a HN 2.5-3.5 
3a Hβ1 3b Hα1 2.5-3.5 
3a Hβ1 3b HPA 2.5-3.5 
3a Hβ2 3b HPA 1.7-2.5 
3a HB 3b Hα1 2.5-3.5 
3a HB 3b HPA 2.5-3.5 
3a Hγ 3b Hα1 1.7-2.5 
3b Hα1 4a HN 2.5-3.5 
3b Hα2 4a Hγ 1.7-2.5 
3b Hα1 4a HB1 4.5-5.5 
3b Hα1 4a HB2 4.5-5.5 
3b HPA 4a HD1 4.5-5.5 
3b HPB 4a HD1 4.5-5.5 
3b HPA 4a HD2 4.5-5.5 
3b HPB 4a HD2 4.5-5.5 
4b Hα1 5a HN 1.7-2.5 
4b Hα2 5a HN 2.5-3.5       
5a Hβ1 5b Hα1 1.7-2.5 
5a Hβ1 5b HPA 2.5-3.5 
5a Hβ2 5b HPA 2.5-3.5 
5a Hβ1 5b HPE 3.5-4.5 
5a Hβ2 5b HPE 3.5-4.5 
5a Hγ 5b Hα1 1.7-2.5 
5b Hα1 6a HN 2.5-3.5 
5b Hα2 6a HN 2.5-3.5 
5b Hα1 6a HB 2.5-3.5 
5b HPA 6a HB 4.5-5.5 
5b HPE 6a HB 4.5-5.5 
5b HPA 6a Hγ 4.5-5.5 
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Table 4.3 (Continued) 
6b Hα1 7a HN 2.5-3.5 
6b Hα2 7a HN 1.7-2.5 
6b Hα1 7a Hγ 1.7-2.5 
7a Hβ1 7b HPA 2.5-3.5 
7a HB 7b HPA 2.5-3.5 
7a HB 7b HPB 4.5-5.5 
7b Hα1 8a HN 2.5-3.5 
7b HPA 8a HB 2.5-3.5 
7b HPB 8a HB 4.5-5.5 
7b HPA       8a Hγ 2.5-3.5 
7b HPB       8a Hγ 4.5-5.5 
8a HN 8b Hα1 4.5-5.5 
 
Table 4.3 List of non-sequential NOEs. 
Residue H-atom Residue H-atom Restraints(Å) 
0 Hα 1b HPA 4.5-5.5 
0 Hα 1b HPB 4.5-5.5 
0 Hα 2a HN 4.5-5.5 
1b HPB 3a HB 4.5-5.5 
1b HPA 4a HD1 4.5-5.5 
1b HPB 4a HD1 4.5-5.5 
2a HG 3b HPA 4.5-5.5 
2a HD 3b HPA 4.5-5.5 
3b HPA 5a Hβ1 4.5-5.5 
4a HG 5b HPA 4.5-5.5 
4a HG 5b HPE 4.5-5.5 
5b HPA 7a HB 4.5-5.5 
5b HPE 7a HB 4.5-5.5 
5b HPC 7a HB 4.5-5.5 
5b HPA 8a Hγ 4.5-5.5 
5b HPE 8a Hγ 4.5-5.5 
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Table 4.3 (Continued) 
7a HB 8a HN 2.5-3.5 
7b HPA 8b Hα1 2.5-3.5 
7b HPB 8b Hα1 4.5-5.5 
 
Table 4.4 Rmsd of MD calculated structures. 
Residues Backbone Side chain 
1a 1.163 1.071 
1b 0.973 0.842 
2a 0.678 0.800 
2b 0.989 1.315 
3a 0.437 0.405 
3b 0.594 0.683 
4a 0.635 0.707 
4b 0.596 0.874 
5a 0.351 1.062 
5b 0.549 0.630 
6a 0.550 0.612 
6b 0.794 1.525 
7a 0.605 0.497 
7b 0.675 1.462 
8a 0.483 0.668 
8b 1.442 0.832 
 
 
 
 
 
 
 
 
111 
 
Table 4.5 Backbone torsion angles (deg) for the average structure of the sulfono-γ-AApeptide 4-
1. 
 
residues      
1 -75.4 -178.0 -71.0 146.0 -14.3 
2 -68.7 -175.8 151.2 -85.6 29.8 
3 -71.3 177.3 142.8 59.0 -122.1 
4 -101.7 61.4 114.5 -68.6 -26.3 
5 -125.2 94.3 -53.4 145.0 -68.7 
6 66.5 40.1 83.6 -39.2 -88.7 
7 25.3 167.9 123.9 -70.3 109.9 
8 169.6 65.1 110.2 67.5 50.9 
 
Circular dichroism analysis. Circular Dichroism (CD) analysis was conducted on an Aviv 215 
circular dichroism spectrometer using a 1 mm path length quartz. Ten scans were averaged to 
obtain the data of each sample. Experiments were repeated for three times and the obtained 
spectra were averaged. The final spectra were normalized by subtracting the average of the blank 
spectra. Molar ellipticity [θ] (deg.cm2.dmol-1) was calculated using the following equation: 
[θ] = θobs/(n l c 10) 
In which θobs is the measured ellipticity in millidegrees, while n is the number of side 
groups, l is path length in centimeter, and c is the concentration of the sulfono-γ-AA peptide in 
molar units. 
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X-ray Crystallography. The crystal of 4-6 was obtained by slow solvent evaporation of 1:1 
CH2Cl2/isopropanol containing 5 mg/mL of 4-6. The X-ray diffraction data for 4-6 were 
collected on a Bruker D8 Venture PHOTON 100 CMOS system equipped with a Cu Kα 
INCOATEC Imus micro-focus source (λ = 1.54 Å). Indexing was performed using APEX2 
(Difference Vectors method).35 Data integration and reduction were performed using SaintPlus 
6.01.36 Absorption correction was performed by multi-scan method implemented in SADABS. 
Space groups were determined using XPREP implemented in APEX2. The structure was solved 
using SHELXS-97 (direct methods) and refined using SHELXL-2013 (full-matrix least-squares 
on F2) contained in APEX2, WinGX v1.70.0137 and OLEX2.38 All non-hydrogen atoms were 
refined anisotropically. Hydrogen atoms of –CH, -CH2, -CH3, -OH and -NH groups were placed 
in geometrically calculated positions and included in the refinement process using riding model 
with isotropic thermal parameters: Uiso(H) = 1.2Ueq(-CH,-CH2, -NH) and Uiso(H) = 1.5Ueq(-
CH3, -OH). Disordered benzyl group has been refined using constraints (AFIX66 for phenyl 
group) and restraints RIGU and SADI. The ADP values for disordered C21A and C21B atoms 
have been set to be equal (EADP). CCDC-1018941 contains the supplementary crystallographic 
data for this paper. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data%5Frequest/cif. 
Table 4.6 Crystal data and structure refinement for 4-6. 
Identification code 4-6
Empirical formula C30H36N2O7S 
Moiety formula C27H28N2O6S, C3H8O 
Formula weight 568.67 
Temperature/K 100.01 
Crystal system monoclinic 
Space group P21 
a/Å 5.0381(2) 
b/Å 22.7047(9) 
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Table 4.6 (Continued) 
  
c/Å 12.7281(5) 
α/° 90 
β/° 98.445(3) 
γ/° 90 
Volume/Å3 1440.16(10) 
Z 2 
ρcalcmg/mm3 1.311 
m/mm-1 1.412 
F(000) 604.0 
Crystal size/mm3 0.09 × 0.02 × 0.02 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection 7.02 to 138.25° 
Index ranges -6 ≤ h ≤ 6, -27 ≤ k ≤ 27, -15 ≤ l ≤ 15 
Reflections collected 17125 
Independent reflections 5187 [Rint = 0.1138, Rsigma = 0.1053] 
Data/restraints/parameters 5187/78/394 
Goodness-of-fit on F2 1.056 
Final R indexes [I>=2σ (I)] R1 = 0.0594, wR2 = 0.1199 
Final R indexes [all data] R1 = 0.0877, wR2 = 0.1324 
Largest diff. peak/hole / e Å-3 0.37/-0.31 
Flack parameter 0.06(2) 
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CHAPTER 5: DESIGN AND SYNTHESIS OF UNPRECENDENTED CYCLIC γ–
AAPEPTIDES FOR ANTIMICROBIAL DEVELOPMENT 
 
 
Note to Reader 
Contents in this chapter have been previously published in Chemical Science, 2012, 3, 
2570-2575 and have been reproduced with the permission of the Royal Society of Chemistry 
(RSC). 
5.1 Background 
One of the major health concerns for eukaryotes is the infection by pathogenic bacteria, 
which became acute in recent years due to the bacteria’s rapid development of multi-drug 
resistance to conventional antibiotics.1,2 Indeed, the World Health Organization (WHO) recently 
identified antimicrobial resistance as one of the three greatest threats facing mankind in 21st 
century. While chemotherapeutic agents primarily target the specific metabolic processes in 
bacteria, there is also a class of “host-defense” peptides produced in the eukaryotic innate 
immune response, which kill invading pathogens mainly through disruption of bacterial 
membranes.1,2 It is generally accepted that these antimicrobial peptides (AMPs) can be induced 
to segregate their cationic and lipophilic side-chain functional groups upon binding to negatively 
charged bacterial membranes, and the resulting globally amphipathic conformation leads to the 
disruption of bacterial membranes. 3,4 Although the details of membrane disruption remain 
elusive, it is widely recognized that the hydrophobic part of AMP drives the peptide’s 
penetration through membrane via a hydrophobic interaction.4,5 The penetration process causes 
the depolarization of bacterial membranes and often leads to their cell death.5 The electrostatic 
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interaction of AMPs with bacterial membrane is thereby considered the driving force of their 
selectivity for bacteria against mammalian cells, in which anionic phospholipids only exist in the 
inner leaflet of membrane, and the overall charge of their membranes is zwitterionic.4,5 Due to 
this unique antimicrobial mechanism which depends on the peptide’s global chemical properties 
instead of their specific sequences, AMPs are difficult for bacteria to develop resistance against.1 
Further, AMPs exhibit broad-spectrum activities against bacteria (both Gram-positive and Gram-
negative), fungi, and even viruses.1,2 Hence, they are regarded as ideal agents to supplement 
current antimicrobial remedy.3 
Despite all the promising potentials, AMPs’ intrinsic peptidic nature severely limits their 
practical application as therapeutics, by making them immunoreactive, and susceptible to 
proteolytic degradation.6 To circumvent the drawbacks, non-natural peptidomimetics were 
recently developed to mimic AMPs, in terms of both antimicrobial activities and intrinsic 
mechanisms, while their backbones were modified to be protease-resistant.7 Over the last decade, 
non-natural antimicrobial oligomers have been extensively investigated, such as β-peptides, 
peptoids, arylamides, and other synthetic polymers.5,8 Whereas initial approaches focused on 
peptide mimics that can adopt regular helical conformations, it was later discovered to be 
unnecessary for potent antimicrobial activity, as long as a global segregation of hydrophilic and 
hydrophobic side chains can be ultimately achievable on the molecular surface, during the 
interactions with bacterial membranes.9,10 Despite the growing interest and intensive studies on 
linear peptidomimetics, it remains a challenge to introduce a diverse set of functional groups to 
tune their activity and selectivity, with the reported structure-activity relationship sometimes 
being inconsistent.11 In addition, some active peptidomimetics do not exhibit good selectivity 
between bacteria and mammalian cells,12 and there is still much room to further increase their 
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antimicrobial activity. Exploration of antimicrobial agents with potent, broad-spectrum anti-
bacteria activity, while maintaining an excellent selectivity against bacteria, is an urgent goal in 
chemical biology. 
We recently reported a new class of peptidomimetics, termed “γ-AApeptides”.13 
Compared to conventional natural peptides, γ-AApeptides are advantageous in both their 
limitless potential for diversification and their inherent resistance to biodegradation. The 
synthesis of γ-AApeptides is straightforward, which facilitates library development for drug 
screening purposes. Certain γ-AApeptides have been demonstrated to disrupt protein-protein 
interactions,13 and to mimic protein’s binding activity with nucleic acids.14 A small library of 
linear γ-AApeptides was designed, which led to the identification of a potent γ-AApeptide (γ5) 
that displays significant activity against both bacteria and fungi, including the multi-drug 
resistant clinically-relevant strains.15 In the effort of our continuous exploration of antimicrobial 
γ-AApeptides, we herein report for the first time the design, synthesis, and evaluation of cyclic γ-
AApeptides, some of which display antimicrobial activities superior to the previously reported 
linear ones. 
Cyclic antimicrobial peptides were commonly observed in nature, such as gramicidin S, 
tyrocidine, polymyxin B, and protegrin I, which generally adopt semi-rigid backbone 
conformations, with substituents positioned in well-defined space.16 Such a semi-rigid backbone 
as a result of cyclization favors the binding event in entropy, while still possessing some 
flexibility to optimize their conformations for binding.16,17 It was shown that the lack of disulfide 
bonding diminished their hairpin conformation, and reduced the membranolytic activity.18-20 
Hence, the cyclic peptides may have enhanced antimicrobial activity compared to the linear 
ones. There has been significant effort in the development and investigation of cyclic 
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antimicrobial peptides.16,21-23 For instance, Robinson et al21,22 prepared several cyclic peptides or 
peptide-peptoid chimeras, whose structures, as revealed by NMR, were unordered in water, but 
readily inducible to form regular β-hairpins in the membrane-mimicking environment. It is 
believed that the conformational bias induced by the constrained template would stabilize the 
hairpin structure, leading to the cluster of functional groups to form a hydrophobic and a 
hydrophilic face, upon interaction with bacteria membrane.21,24 Whereas the hemolytic activity 
of peptide oligomers is determined by their lipophilicity, the antimicrobial effects are always 
mediated by peptide charges and global amphiphilicity.24 It is therefore very interesting to 
investigate the antimicrobial activity of the cyclic peptidomimetics, as they are expected to be 
more stable against proteolysis than cyclic peptides, and more antimicrobial than linear 
peptidomimetics. 
5.2 Results and Discussion 
 
Figure 5.1. Illustration of cyclic antimicrobial -AApeptide design. A, Basic representation of 
the amphiphilic -AApeptide building block; B, Amphipathic cyclic -AApeptide with globally 
amphipathic conformation. 
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Herein for the first time we designed cyclic antimicrobial γ-AApeptides based on the 
simple rationale that we previously developed to successfully generate linear antimicrobial 
AApeptides (Figure 5.1).15,25 In this rationale, potent antimicrobial activity can be achieved by 
joining amphiphilic building blocks together to form a globally amphipathic conformation upon 
the interaction with bacterial membranes. The activity and selectivity can be fine-tuned by 
varying the ratio of cationic/hydrophobic groups. To achieve a global distribution of cationic and 
hydrophobic groups along the backbone, we prepared amphiphilic building blocks with a 
cationic group and a hydrophobic group on either side (Figure 5.1A). By joining these building 
blocks together and cyclizing the resulting oligomer (Figure 5.1B), a global amphiphilicity is 
expected to be achieved upon binding to bacterial membranes.15 As such, the amphiphilic 
building block 2 was prepared according to previously published procedure,15 in which the 
amino acid is lysine, and the phenyl ended side chain is appended to the amine (Figure 5.2a). 
Given that an introduction of hydrophobic building block can tune the overall amphiphilicity of 
γ-AApeptides and improve their antimicrobial activity, we also prepared building blocks 3 
(Figure 5.2b) based on the reported procedure. To facilitate the on-resin cyclization of γ-
AApeptide, a special γ-AApeptide building block 1 was designed here. While the synthesis was 
carried out similarly to the previously reported,15 the mono-allyl succinate was employed to 
modify the amine (Figure 5.2b). 
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Figure 5.2. γ-AApeptide building blocks used in the preparation of cyclic γ-AApeptides. a, The 
structures of building blocks; b, the synthesis of building block 1 and 3. 
After building block 1 was conjugated to the beads, other building blocks were 
sequentially assembled via the standard Fmoc chemistry.15 In the end, the allyl ester from the 
peptide was deprotected by standard Pd(PPh3)4/PhSiH3 reduction, and the resulting free 
carboxylate group reacted with the primary amino group of the last assembled building block, 
which resulted in protected cyclized γ-AApeptides on the resin (Figure 5.3). The desired cyclic 
γ-AApeptides were obtained upon treatment with TFA and HPLC purification, which are shown 
in Figure 5.4. 
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Figure 5.3. General synthesis of cyclic γ-AApeptides via on-resin cyclization. 
Cyclized γ-AApeptides (5-1, 5-2, 5-3) comprising of four, five, and six amphiphilic 
building blocks were prepared as an initial attempt, and tested for their antimicrobial activities 
against a series of Gram-positive and Gram-negative bacteria and fungi, many of which are 
multi-drug resistant and clinically-relevant strains (Table 5.1). The oligomers’ hemolytic 
activities towards human red blood cells were also measured, as an indication of their selectivity. 
For comparison, Pexiganan, a phase III antimicrobial peptide drug candidate,3,26-28 as well as γ5, 
the most potent linear γ-AApeptide, 15 were both used as controls. Similar to linear γ-AApeptide, 
which appeared to be more potent with a longer sequence,15 the cyclic γ-AApeptide with an 
increasing ring size (from 5-1 to 5-3 tended to augment the antimicrobial activities (Table 5.1). 
The most potent cyclic γ-AApeptide 5-3 has a similar activity to the well-known Pexiganan, 
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though it is still inferior to γ5. It is notable that the hemolytic activity of 5-3 is much less than 
Pexiganan and γ5, implying the potential to improve its anti-bacteria activities through the 
introduction of hydrophobic building blocks.15 
Table 5.1 The antimicrobial and hemolytic activities of oligomers. The microbial organisms 
used are C. albicans  (ATCC 10231), B. subtilis (BR151), multi-drug resistant S. epidermidis 
(RP62A), Vancomycin-Resistant E. faecalis (ATCC 700802), Methicillin-Resistant S. aureus 
(ATCC 33592), K. pneumoniae (ATCC 13383), and multi-drug resistant P. aeruginosa (ATCC 
27853). The minimum inhibitory concentration (MIC) for bacteria is the lowest concentration 
that completely inhibits growth after 24 h; and MIC for fungus C. albicans is the lowest 
concentration that completely inhibits growth after 48 h. Sequences showing the most broad-
spectrum antimicrobial activity (3-6) are shaded in light grey. Pexiganan and Linear γ5 were 
used as control. 
Organism MIC (µg/mL) 
HW- 
B-3 
HW- 
B-4 
HW-
B-5 
HW-
B-11 
HW-
B-12 
HW-
B-13 
HW-
B-14 
Pexigan
an3,26-28  
Linear 
γ515  
Gram-positive          
B. subtilis 25-50 10 5 2 5 1 2 4 2 
S. epidermidis 
(MRSE) 
>50 10 8 2 5 2 2 8 5 
E. faecalis 
(VREF) 
>50 20 20 15 8 5 5 32 5 
S. aureus 
(MRSA) 
>50 >50 25-50 5 6 1 3 16 5 
Gram-negative          
K. pneumoniae  >50 >50 >50 20 5 8 10 8 5 
P. aeruginosa  >50 20 18 10 >50 8 10 8-16 >50 
Fungus          
C. albicans >50 >50 >50 5 5 2 4 124 8 
Hemolysis 
(H10/H50) 
>500/
>500 
>500/ 
>500 
>500/
>500 
200/ 
>500 
150/ 
450 
40/ 
100 
45/ 
300 
181/495 75/300
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Figure 5.4. The structures of cyclic γ-AApeptides and previously prepared linear antimicrobial γ-
AApeptide γ5. Underlined building blocks are hydrophobic building blocks containing two 
hydrophobic side chains; the rest of the building blocks in the sequences are amphiphilic with one 
cationic and one hydrophobic side chains. 
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Given that linear γ5 bears hydrophobic building blocks, and thus exhibited much more 
potent antimicrobial activities than other linear γ-AApeptides completely made from amphiphilic 
building blocks,15 we attempted this similar effort to our cyclic γ-AApeptides. 5-4, 5-5, and 5-6 
were thereby prepared to incorporate the same number of building blocks as 5-3, but have one or 
two amphiphilic building blocks replaced by the hydrophobic ones (Figure 5.4). As a result, 5-4, 
with the change of only one building block, showed enhanced antimicrobial activities, especially 
against Gram-positive bacteria, which are comparable to linear γ5, and better than Pexiganan 
(Table 5.1). In spite of its weaker activity towards Gram-negative strain K. pneumoniae, 5-4 has 
a stronger inhibition of fungus C. albicans than both Pexiganan and linear γ5, with a significant 
minimum inhibitory concentration (MIC) value of 5 µg/mL.  In addition, 5-4 still possesses a 
low hemolytic activity, thereby making it a promising antimicrobial agent with comparable or 
even better selectivity than Pexiganan and linear γ5. Following this success, 5-5 was developed 
to incorporate two hydrophobic building blocks, which are separated by two hydrophilic building 
blocks, in a way similar to the design of linear γ5. Surprisingly, its antimicrobial activities were 
not improved, or even weaker with respect to 5-4. In order to assess whether the diminuendo of 
activity is due to the incorporation of more hydrophobic building blocks or is caused by their 
relative positions in the ring, 5-6 was synthesized by placing two hydrophobic building blocks 
adjacent to each other (Figure 5.4). As a result, 5-6 exhibited even better activities than 5-4, 
Pexiganan, and linear γ5 to arrest the growth of both Gram-positive and Gram-negative bacteria 
pathogens, as well as in fungus (Table 5.1). Especially towards two most clinically relevant 
strains S. aureus (MRSA) and P. aeruginosa (PA), 5-6 achieved a MIC value of 1 µg/mL and 8 
µg/mL, respectively; which is at least 5-fold more potent than the linear γ5. Though 5-6 appears 
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to be more hemolytic, its overall selectivity in several important pathogens is still improved 
relative to linear γ5 and Pexiganan.  
To further investigate the effect of hydrophobicity and to tune the activity, 5-7 (Figure 
5.4) with three hydrophobic building blocks was developed, which, however, resulted in a 
slightly decreased antimicrobial activity and hemolytic activity (Table 5.1) in comparison to 5-6. 
Nevertheless, the activity and selectivity of 5-7 are still generally comparable, or superior to 
linear γ5, against several strains including MRSA and PA. Thus, it is also a promising candidate 
for future antibiotic development. Based on the results, it appears that the inclusion of two 
neighboring hydrophobic building blocks brings in the optimal antimicrobial activity. The 
structure-activity studies of 5-3, 5-4, 5-6, and 5-7 suggest that a higher percentage of 
hydrophobic groups in γ-AApeptides lead to a higher antimicrobial activity. It is well accepted 
that more lipophilicity would lead to an increased hemolytic activity.3,9 While the result of our 
structure-activity studies generally supports this rule, the slightly decreased hemolytic activity 
demonstrated by 5-7, which has one more hydrophobic building block than 5-6, is quite 
unexpected. It suggests that besides the absolute hydrophobicity, the overall conformations of 
molecules may also affect their hemolytic activity. Finally, the distinct activities between 5-5 and 
5-6 suggest the importance of position for hydrophobic building blocks. A preliminary computer 
modeling of 5-6 reveals that the cyclic γ-AApeptide naturally adopts a globally amphipathic 
conformation, with cationic side groups clustered at the bottom left face of the ring, and the 
majority of hydrophobic groups at the top face of the ring (Figure 5.5). Such a constrained 
structure with predefined amphiphilicity may favor the binding and disruption events within 
bacteria membranes. On the contrary, the amphiphilic topology of 5-5 may be scrambled by the 
separated hydrophobic building blocks. Though linear γ-AApeptides with scrambled 
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amphipathicity can still be induced by membrane to adopt a global amphiphilicity,15 the rigid 
structure of cyclic γ-AApeptides compromises their conformational flexibility, thereby requiring 
a pre-defined sequence for interaction with bacteria membrane. 
 
Figure 5.5. The energy-minimized structure of 5-6. The computer modeling was carried out 
using ChemBioOffice MM2 energy minimization.  
In order to understand the antimicrobial mechanisms of cyclic γ-AApeptides, the most 
active ones, 5-4, 5-6, and 5-7, were used to investigate their effects in cytoplasmic membrane 
disruption through the depolarization of S. aureus membrane (Figure 5.6).5 The membrane 
potential-sensitive dye DiSC3 was used, the distribution of which between the medium and the 
cell interior reflects the membrane potential.5 The loss of membrane potential as a result of 
membrane permeation/disruption will lead to a dramatic increase in fluorescent intensity.5 
Although the oligomer concentration needed for depolarization is actually higher than the 
oligomers’ MIC values, which is consistent to the previous report,5 generally more active 
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antimicrobial oligomers with lower MIC values tended to reach a high percentage of 
depolarization at a lower concentration. Such a trend was clearly demonstrated by 5-4, 5-6, and 
5-7, which supports the membrane disruption mechanism of cyclic γ-AApeptides (Figure 5.6). 
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Figure 5.6. Depolarization of the cytoplasmic membrane of S. aureus by cyclic γ-AApeptides. 
The antimicrobial mechanism of cyclic γ-AApeptide was further assessed by 
fluorescence microscopy, in which B. subtilis was treated with the most potent 5-6, and in the 
meantime stained with 4’, 6’-diamidino-2-phenylindole dihydrohloride (DAPI) and propidium 
iodide29 dyes (Figure 5.7). DAPI stains all bacterial cells irrespective of their viability, while PI 
selectively stains injured or dead cells with damaged membranes.30,31 Whereas little PI staining 
(red fluorescence) was observed in the control group, B. subtilis incubated with 5-6 for 2 h 
displayed a strong red staining by PI, indicating the significant disruption of bacterial membrane 
by 5-6. The aggregation of dead bacterial cells after the oligomer treatment is consistent with 
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literature reports,15,31 an indication of loss of membrane potential. Collectively, these cyclic γ-
AApeptides have a bacterial inhibition mechanism similar to antimicrobial peptides, but distinct 
from conventional antibiotics, which augments their promise for further antimicrobial 
development. 
 
Figure 5.7. Fluorescence micrographs of B. subtilis treated with 5 µg/ml cyclic γ-AApeptide 5-6 
for 2 h. a1, control, no treatment, DAPI stained; a2, control, no treatment, PI stained; a3, control, 
no treatment, the merged view. b1, 5-6 treatment, DAPI stained; b2, 5-6 treatment, PI stained; 
b3, 5-6 treatment, the merged view. Scale bar: 2 µm.  
5.3 Conclusions 
In summary, we have shown for the first time the design, synthesis and evaluation of a 
class of cyclic γ-AApeptides for antimicrobial development. Following a proper tuning of 
hydrophobicity, several cyclic γ-AApeptides turned out to be superior to previously reported 
linear γ-AApeptides and peptide drug candidate under clinic testing, in terms of antimicrobial 
activity and selectively. Coupled with current biocompatibility, stability, and virtually limitless 
side chain variation, it is conceivable that the antimicrobial activity, selectivity, and overall 
drugability of cyclic γ-AApeptides can be further improved in the future. With a specifically 
designed building block for cyclization, the corresponding synthesis is facile and 
straightforward, which may propel the application of cyclic γ-AApeptides to a broad field of 
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biomedical research. The finding of enhanced activity through cyclization of γ-AApeptide may 
also shed light on the design and optimization of other non-natural oligomers for future 
development of promising antimicrobial agents. 
5.4 Experimental Section 
General information. -amino acid esters and Knorr resin (0.66 mmol/g, 200-400 mesh) were 
provided by Chem-Impex International, Inc. All other reagents and solvents were purchased 
from either Sigma-Aldrich or Fisher Scientific. The γ-AApeptide building block was synthesized 
following previously reported procedure.32 NMR spectra of the γ-AApeptide building block were 
obtained on a Varian Inova 400 instrument. Cyclic γ-AApeptides were prepared on a Rink amide 
resin in peptide synthesis vessels on a Burrell Wrist-Action shaker. The cyclic γ-AApeptides 
were analyzed and purified on an analytical and a preparative Waters HPLC system, 
respectively, and then dried on a Labcono lyophilizer. Molecular weights of cyclic γ-AApeptides 
were identified on a Bruker AutoFlex MALDI-TOF mass spectrometer. 
Synthesis14,15,32 and characterization of the γ-AApeptide building blocks. The γ-AApeptide 
building blocks (Figure 5.2a) were synthesized following previously reported procedure.14,15,32 
The characterization of building blocks 2 has been reported.15 The synthesis of building block 1 
and 3 is shown in Figure 5.2b. 
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Compound 1. Yield 60 % (two steps from 4). 1H NMR (DMSO-d6, 400MHz) δ (two 
rotamers) 7.88 (d, 2H), 7.62-7.57 (m, 2H), 7.42-7.29 (m, 4H), 7.28-7.15 (m, 5H), 5.93-5.83 (m, 
1H), 5.31-5.25 (m, 1H), 5.19-5.15 (m, 1H), 4.52-4.49 (m, 2H), 4.21-4.03 (m, 4H), 3.88 (d, 2H), 
3.63-3.35 (m, 2H), 3.10-2.47 (m, 6H). 13C NMR (DMSO-d6, 100MHz) δ 171.8, 171.7, 171.2, 
171.0, 170.6, 155.6, 155.6, 143.8, 143.7, 143.7, 143.7, 140.6, 140.6, 138.7, 138.6, 132.6, 132.6, 
129.0, 128.0, 127.9, 127.5, 126.9, 126.0, 125.8, 125.0, 125.0, 120.0, 117.4, 117.4, 65.3, 64.2, 
64.2, 51.7, 51.4, 46.6, 46.5, 37.3, 28.9, 28.8, 27.4, 27.1. HR-ESI: [M+H]+ cacl: 571.2439, found: 
571.2410. 
 
 
Compound 3. Yield 60 %. 1H NMR (DMSO-d6, 400 MHz) δ (two rotamers) 7.83 (d, J = 
7.6 Hz, 2H), 7.58-7.53 (m, 2H), 7.36-7.26 (m, 5H), 7.24-7.09 (m, 5H), 4.13-4.06 (m, 3H), 3.96-
3.74 (m, 4H), 3.51-3.46 (m, 1H), 3.40-3.32 (m, 1H), 3.38-3.11 (m, 1H), 2.78-2.72 (m, 1H), 2.67-
2.56 (m, 1H), 2.32-2.06 (m, 2H), 1.47-1.36 (m, 1H), 1.33-1.24 (m, 2H), 0.80-0.71 (m, 6H). 13C 
NMR (DMSO-d6, 100 MHz) δ 173.7, 156.1, 144.2, 141.1, 139.5, 139.1, 129.53, 129.46, 128.4, 
128.0, 127.4, 126.5, 126.3, 125.7, 125.6, 125.5, 120.5, 120.5, 65.8, 65.8, 51.5, 51.0, 47.0, 38.3, 
34.3, 34.1, 30.9, 30.9, 27.6, 27.5, 22.8, 22.7. HR-ESI: [M+H]+ cacl: 529.2697, found: 529.2700. 
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Compound 4. Yield 82 %. 1H NMR (CDCl3, 400MHz) δ 7.72 (d, J = 8 Hz, 2H), 7.49-
7.45 (m, 2H), 7.38-7.34 (m, 2H), 7.26-7.14 (m, 7H), 6.18-6.14 (m, 1H), 4.26-4.16 (m, 3H), 4.09-
4.06 (m, 1H), 3.78-3.68 (m, 2H), 3.42-3.37 (m, 1H), 3.17-3.15 (m, 1H), 2.99-2.94 (m, 1H), 2.86-
2.81 (m, 1H), 1.39 (s, 9H). 13C NMR (CDCl3, 100MHz) δ 165.2, 165.1, 162.1, 161.7, 156.9, 
156.8, 143.9, 143.6, 141.2, 141.1, 136.0, 129.0, 128.8, 127.7, 127.6, 127.1, 125.2, 119.8, 84.8, 
67.3, 50.6, 49.8, 47.8, 46.8, 38.6, 36.9, 36.8, 27.8, 27.7. HR-ESI: [M+H]+ cacl: 487.2591, found: 
487.2565. 
Solid phase synthesis, purification and characterization of cyclic γ-AApeptides. Cyclic γ-
AApeptides were prepared on a Rink amide resin in peptide synthesis vessels, on a Burrell 
Wrist-Action shaker, following the standard Fmoc chemistry protocol of solid phase peptide 
synthesis. Synthesized γ-AApeptide building blocks were used (Figure 5.3a). Each coupling 
cycle included a Fmoc deprotection using 20% Piperidine in DMF, and 8 h coupling of 1.5 equiv 
of γ-AApeptide building blocks in the presence of 4 equiv of DIC (diisopropylcarbodiimide) 
/DhbtOH (3-4-Dihydro-3-hydroxy-4-oxo-1-2-3-benzotriazine) in DMF. The cyclization was 
achieved on resin via the γ-AApeptide building block 1. Briefly, 1 was first attached to the solid 
support, followed by standard Fmoc solid phase synthesis. After desired sequences were 
assembled, the allyl group was removed by treatment of Pd(PPh3)4 (0.2 equiv.) /PhSiH3 (10 
equiv.) /CH2Cl2 for 2h (repeated two times). The deprotection of Fmoc group was then carried 
out on the N-terminus. The intramolecular cyclization was accomplished using 
133 
 
PyBop/HOBt/DIEA/DMF. Next, the resin was transferred into 4 mL vials and cyclic γ-
AApeptides were cleaved from solid support in 50:48:2 TFA/CH2Cl2/triisopropylsilane 
overnight. Then solvent was evaporated and the residues were analyzed and purified on an 
analytical (1 mL/min) and a preparative Waters (20 ml/min) HPLC systems, respectively, using 
5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile) in A (0.1% TFA in water) 
over 40 min, followed by 100% solvent B over 10 min. The HPLC traces were detected at 215 
nm. The desired fractions were eluted as single peaks at  95% purity with yields of 6-10% 
(based on loading of the resin, see Figure 5.4 for sequences). They were collected and 
lyophilized. The molecular weights of cyclic γ-AApeptides (Table 5.2) were obtained on a 
Bruker AutoFlex MALDI-TOF mass spectrometer using –cyano-4-hydroxy-cinnamic acid. 
Table 5.2 MALDI analysis of cyclic γ-AApeptides 5-1 to 5-7. 
Cyclic γ-
AApeptides 
Yield (based on 
loading of the resin) 
molecular weight 
(Actual) 
molecular weight (found) 
 
5-1 10.5% 1501.2 1053.1 (M+H+) 
5-2 8.6% 1805.1 1806.6 (M+H+) 
5-3 6.2% 2108.3 2109.6 (M+H+) 
5-4 6.8% 2093.3 2147.6 (M+2H2O+NH4+) 
5-5 6.5% 2078.3 2079.9 (M+H+) 
5-6 6.0% 2078.3 2079.0 (M+H+) 
5-7 6.4% 2063.3 2117.3 (M+2H2O+NH4+) 
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Figure 5.8. HPLC traces of pure cyclic γ-AApeptides. 
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Antimicrobial assays. The microbial organisms used were B. subtilis (BR151), multi-drug 
resistant S. epidermidis (RP62A), C. albicans (ATCC 10231), Vancomcin-resistant E. faecalis 
(ATCC 700802), Methicillin-resistant S. aureus (ATCC 33592), K. pneumoniae (ATCC 13383), 
multi-drug resistant P. aeruginosa ATCC 27853. The minimum inhibitory concentration (MIC) 
is the lowest concentration that completely inhibits the growth of bacteria in 24 h. The highest 
concentration tested for antimicrobial activity was 50 µg/mL. The antimicrobial activities of the 
cyclic γ-AApeptides were determined in a sterile 96 -well plates by broth micro-dilution method. 
Bacterial cells 33 and fungi 34 were grown overnight at 37 ºC in 5 mL medium, after which a 
bacterial suspension (approximately 106 CFU/mL) or fungal suspension Candida albicans 
(ATCC 10231)  (approximately 103 CFU/mL) in Luria broth or trypticase soy was prepared. 
Aliquots of 50 µL bacterial or fungal suspension were added to 50 µL of medium containing the 
cyclic γ-AApeptides for a total volume of 100 µL in each well. The cyclic γ-AApeptides were 
prepared in PBS buffer in 2 –fold serial dilutions, with the final concentration range of 0.5 to 50 
µg/mL. Plates were then incubated at 37 ºC for 24 h (for bacteria) or 48h (for Candida albicans 
(ATCC 10231). The lowest concentration at which complete inhibition of bacterial growth 
(determined by a lack of turbidity) is observed throughout the incubation time is defined as the 
minimum inhibitory concentration (MIC). The experiments were carried out independently three 
times in duplicates. 
Lipid depolarization5,35,36. The Lipid depolarization of the bacterial cell membrane was 
conducted using the membrane potential sensitive dye 3, 5’-dipropylthiacarbocyanine iodide 
(DiSC3-5) that distributes between the cells and the medium depending on the membrane 
potential gradient. S. aureus (ATCC 33592) cells were grown in Luria broth and Trypticase soy 
broth medium respectively to a mid –logarithmic phase (OD600=0.5-0.6). The bacterial cells were 
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then collected by centrifugation at 3000 rpm for 10 min and then washed once with buffer (5mM 
HEPES and 5mM Glucose,pH 7.2). The cells were re-suspended to OD600 =0.05 with 100 mM 
KCl, 2 µM DiSC3-5,5mM HEPES and 5 mM Glucose and were incubated for 30 min at 37 º C 
for maximal dye uptake and fluorescence self-quenching. This bacterial suspension (90 µL) and 
10 µL of compound stock solutions or control drug solution were added to white flat bottomed 
polypropylene 96-well plate (Costar) and incubated at 37 ºC for 30 min. The fluorescence 
reading was monitored using the microplate reader (Biotek) at an excitation wavelength of622 
nm and an emission wavelength of 670 nm); the fluorescence increased due to the disruption of 
cytoplasmic membrane. Valinomycin (final concentration 250 µg/mL) was used as a positive 
control, and the blank with only cells and dye was used as the background. 
Hemolysis assay. Freshly drawn human red blood cells (hRBC’s) with additive K2 EDTA 
(spray-dried) was washed with PBS buffer several times and centrifuged at 1000 g for 10 min 
until a clear supernatant was observed. The hRBC’s were resuspended in 1× PBS to get a 5% v/v 
suspension. Two fold serial dilutions of γ-AApeptides dissolved in 1× PBS from 250 µg/ml to1.6 
µg/ml were added to a sterile 96-well plate to make up to a total volume of 50 µL in each well. 
Then 50 µL of 5% v/v hRBC solution was added to make up a total volume of 100 µL in each 
well. The 0% hemolysis point and 100% hemolysis point were determined in 1 × PBS and 0.2% 
Triton-X-100, respectively. 33 The plate was then incubated at 37 0C for 1 h and centrifuged at 
3500 rpm for 10 min. The supernatant (30 µL) was diluted with 100 µL of 1× PBS and 
absorption was detected by measuring the optical density at 360 nm by Biotek Synergy HT 
microtiter plate reader. % hemolysis was determined by the following equation: 
% hemolysis = (Abs sample   -Abs PBS)/(Abs Triton –Abs PBS) × 100 
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H10 is the concentration of cyclic γ-AApeptide at which 10% hemolysis was observed. 
H50 is the concentration of cyclic γ-AApeptide at which 50% hemolysis was observed. The 
highest concentration tested in the hemolytic assay was 500 µg/mL. 
Fluorescence microscopy. A double staining method with DAPI (4’, 6-Diamidino-2-
phenylindole dihydrochloride, Sigma, >98%) and PI (Propidium iodide, Sigma) as fluorophores 
was used to visualize and differentiate the viable from the dead B. subtilis cells. DAPI as a 
double stranded DNA binding dye, stains all bacterial cells irrespective of their viability, 
whereas Ethidium derivatives such as propidium iodide (PI) is capable of passing through only 
damaged cell membranes and intercalating with the nucleic acids of injured and dead cells to 
form a bright red fluorescent complex.37 The cells were first stained with PI and then with DAPI. 
Bacterial cells were grown until they reached mid-logarithmic phase and then they (~2 × 106 
cells) were incubated with the cyclic γ-AApeptide 5-6 at the concentration of 2 × MIC (10 
µg/mL) for 2 h. Then the cells were pelleted by centrifugation at 3000 g for 15 min in an 
Eppendorf microcentrifuge. The supernatant was then decanted and the cells were washed with 
1× PBS for several times and then incubated with PI (5 µg/mL) in dark for 15 min at 0 oC. The 
excess PI was removed by washing the cells with 1× PBS for several times. Then the cells were 
incubated with DAPI (10 µg/mL in water) for 15 min in dark at 0 oC. The DAPI solution was 
removed and cells were washed with 1× PBS for several times. Controls without the addition of 
5-6 were performed following the exactly same procedure for bacteria. The bacterial cells were 
then examined by using the Zeiss Axio Imager Z1optical microscope with an oil-immersion 
objective (100×).25,38,39 
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APPENDIX A: 1H AND 13C NMR SPECTRA 
 
 
A1 NMR Spectra of γ-AApeptide Building Blocks 
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A2 NMR Spectra of γ-AApeptides 
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